

# Index to Volume 59 (2006)

The index to Volume 59 contains a subject index and an author index.

In the **subject index**, items are listed under key words as found in the US National Library of Medicine's Medical Subject Headings thesaurus.

In the **author index**, all contributing authors are listed alphabetically with the surname first and initial following. If an item has more than one author, the title is documented under the author name that appeared first when published in the *CJHP*. All other authors are listed referring to the name of the principal author, with the abbreviation "Jt Auth" indicating joint authorship.

Codes in parentheses before the page numbers indicate the nature of the item. Codes linked to page numbers with a hyphen indicate a supplement. The following codes are used in this volume:

A – Article

Abs – Abstract

AGM – Annual General Meeting supplement

BR – Book Review

CR – Case Report

E – Editorial

EDR – Executive Director's Report

L – Letter to the Editor

POR – Presidential Officer's Report

PP – Pharmacy Practice

PPC – Professional Practice Conference supplement

SN – Society News



## Subject Index

### Absorptiometry, photon

Measuring the impact of pharmacist intervention: Results of patient education about osteoporosis after fragility fracture (Ho and others) (A) 184

### Abstracts

The ABCs of RBCs: An interactive talk about anemia in chronic kidney disease (Ng and Ong) PPC-37

ACEI versus ARB in high-risk vascular patients (Pickering and Semchuk) PPC-33

Acid suppressive therapy use on an inpatient internal medicine service (Pham and others) AGM-34

Adherence to Canadian Diabetes Association Clinical Practice Guidelines in an outpatient diabetes education centre (Crossman and others) AGM-36

The alphabet soup of cardiac devices (Chiu) PPC-33

Anatomy and physiology of CPOE—Patient safety issues (Ritchie) PPC-46

The anatomy and physiology of CPOE (Barnett) PPC-46

Antibiotic consumption in populations: How does a North American jurisdiction compare with Europe? (Marra) 48

Appel aux armes! Une mise à jour sur les pratiques contre l'invasion des nouvelles maladies infectieuses (Thirion) AGM-21

Approach to anticoagulation in acute coronary syndromes (Pharand) AGM-29

ASA resistance: A laboratory or clinical phenomenon? (Nagge) PPC-26

Atrial fibrillation—Shocking new discoveries (Kertland) PPC-32

Bridging theory to practice: Practical considerations for implementing medication reconciliation strategies (Fernandes) AGM-29

Carbamazepine toxicity related to amiodarone use prior to cardiac surgery (Methot and others) PPC-55

Cardiac diagnostic testing—A primer for pharmacists (Pearson) PPC-24

Cardiovascular prevention and therapy: The mountain population report card—How are we doing at home? (Labelle-Stimac and others) AGM-39

Challenges of NIOSH guidelines for pharmacy (Bornstein) PPC-43

Clinical outcomes and patient satisfaction of a pharmacist-managed emergency department-based outpatient deep vein thrombosis treatment program: 6-year results (Zed) 49

Clinical practice guidelines for community-acquired pneumonia: An investigation into creation, characteristics, quality and compliance with production guides (Jewesson and Gill) PPC-60

Coming attractions: Previews to leadership (Letwin and others) AGM-24

Community-acquired MRSA: An emerging pathogen (Evans) PPC-38

Comparison of a frail-friendly nomogram with physician-adjusted warfarin dosing for prophylaxis after orthopedic surgery on a geriatric rehabilitation unit (Bowles and Freter) 49

The confidentiality of community pharmacy records is at risk: A survey of designated pharmacy managers (Ford and others) PPC-61

Controversies in the management of dementia (Mills) PPC-30

The cost-effectiveness of patient self-managed versus physician-managed oral anticoagulation: A Bayesian approach (Sunderji and Marra) 49

Cyclosporine absorption profiling and its limited sampling strategies in lung transplant recipients (Ensom and others) PPC-49

Le défibrillateur et la maladie hépatique veino-occlusive, vous connaissez? (Côté) AGM-32

Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) buccal spray: Experience in one patient (Min and others) PPC-53

A description of the pharmacological management of acutely agitated patients in a psychiatric emergency department (Cheung and Chaiet) PPC-59

Development of a comprehensive training program for new pharmacist hires (Leblanc and Bhaloo) PPC-64

Development of an educational sabbatical program for pharmacists (Musing and others) 47

The development of a prediction tool for chemotherapy-induced anemia in breast cancer patients receiving adjuvant chemotherapy (Dranitsaris and others) 47, 48

Development of a strategy for safe dofetilide prescribing and monitoring (Rebellato and others) PPC-58

Diagnosis, causes, course and Rx of Alzheimer's disease (AD) (Gauthier) AGM-23

Disaster planning: Lessons learned from Hurricane Katrina (McCrorry, Jr.) AGM-33

Do bugs need drugs? A community program for wise use of antibiotics (Blondel-Hill and Fryters) PPC-34

Drug metabolizing enzymes: Putting pharmacogenetics to practice (Ensom) PPC-40

Drug-related hospitalization to a tertiary care internal medicine service: A prospective study (Samoy and others) 47

Drug toxicity, pharmacovigilance and tailored therapy (Stenton) PPC-40

A drug use evaluation comparing bivalirudin and the combination of heparin plus eptifibatid in elective percutaneous coronary intervention (Slagel and others) AGM-34

A drug use evaluation of milrinone in pediatric critical care patients (Bishara and others) PPC-57

The effectiveness of interventions designed to reduce meperidine use in hospital (Groenestege) PPC-56

Efficient prescription triage (Davis) PPC-38

Entry-level PharmD degree programs in Canada: Some facts and stakeholder opinions (Jewesson and others) PPC-59

Establishment of an admission medication reconciliation program (Guimont and others) AGM-38

Ethical conduct—Point and counterpoint (Ensom and Hall) PPC-44

L'étomidate a-t-il une place dans nos chariots de réanimation? (Marquis) AGM-32

The evaluation and implementation of a process to identify patients eligible for an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone sensitive breast cancer patients in Newfoundland and Labrador (NL) (McCarthy and others) AGM-35

Evaluation of a comprehensive medication review program in urban senior centers (Chang and O'Connell) PPC-53

An evaluation of a multidisciplinary approach to the treatment of osteoporosis in patients following a low trauma hip fracture (Markowski and Richardson) 48

Evaluation of clinical pharmacy services in the home care setting: A pharmacy pilot project (MacAulay and others) AGM-35

Evaluation of the quality of warfarin patient information (Diamantouros and others) AGM-35

Evidence and a regional drug formulary: The Fraser Health Authority experience (Tejani and others) AGM-37

Evidence-based medicine workshop—Appraising systematic reviews (Slavik) AGM-26

Exploring the impact of cultural differences on hospital pharmacists (Laroche) PPC-23

Failure mode effects analysis of the pharmacy preparation of epidural syringes (Vaillancourt and others) AGM-40

The future of residency training in Canada (Woloschuk) AGM-24

Genetic variation in UDP-glucuronosyltransferases and metabolism of mycophenolic acid in lung transplant recipients: A preliminary study (Ensom and others) PPC-48

Heparin-induced thrombocytopenia: Fact or fiction? (Williamson) AGM-27

Highs, lows, & everything in between: Interpreting liver & kidney function in the acute & chronic setting (Burry and Ledger) PPC-28

Holding the line! Updates on emerging infections (Thirion) AGM-19

How to integrate evidence-based medicine into your daily practice: Help for the busy clinician (Arbo and Tejani) PPC-36

Impact of pharmacy intervention on venous thromboprophylaxis (Assaraf and others) AGM-36

Implantation d'un programme de continuité de soins pharmaceutiques pour la clientèle atteinte de maladies respiratoires (Beauchesne and others) AGM-35

Implementation and a randomized controlled evaluation of pharmacist medication assessments in a surgical pre-admission clinic (Kwan and others) PPC-63

Implementation of an insulin protocol in adult critically ill patients (Wynne and others) PPC-51

Implementation of a prohibited list of abbreviations in the David Thompson Health Region (Poloway) AGM-40

Implementation of a "tech-check-tech" program for the preparation and labeling of selected IV admixture products prepared in the pharmacy clean room (Davies and Hales) PPC-54

Implementation of medication reconciliation in a rehabilitation/complex continuing care facility (Karakolis and others) PPC-55

Inadequate empiric antibiotic therapy: Incidence and in-hospital mortality among critically-ill and solid-organ transplant patients (Hamandi and others) AGM-39

Infective endocarditis—New guidelines and old questions (Dressler and Dan) PPC-39

Infliximab: New role in ulcerative colitis (Pham) AGM-20

Infliximab : nouveau rôle dans le traitement de la colite ulcéreuse (Pham) AGM-22

In-hospital management of diabetes (Gordon) PPC-28

In vitro modeling of IV meropenem [500 mg q 6h vs. 1 g q8h] in acinetobacter bacteraemia (Marchesano and others) PPC-64



- Irinotecan stability in vials following puncture when stored at 23°C or 4°C (Walker and others) AGM-36
- IV quinine—Do you know how to get it? (Bubbar) PPC-25
- Joint effort clinical pharmacy services in rural hospitals (Totton and others) AGM-38
- Jongler avec les chiffres : comprendre les résultats des études (Lévesquez) AGM-30
- Lamotrigine induced blood dyscrasias—A case report (Yun and Lamoure) PPC-54
- Leading change in pharmacy practice: The role of the pharmacist in the healthcare system (Tsuyuki) AGM-19
- Learning from medication incident data: The role of the Canadian Medication Incident Reporting and Prevention System (CMIRPS) (Hunt and others) PPC-31
- Limited sampling strategies for mycophenolic acid area-under-the-concentration-time curve in lung transplant recipients (Ensom and others) PPC-48
- Lowering of serum valproic acid levels during concomitant therapy with meropenem: A clinically relevant drug interaction (Trobe and others) PPC-65
- Management of acute agitation and delirium: Are atypical antipsychotics just along for the ride? (Corrigan) AGM-21
- Measuring your department's progress in the advancement of pharmacy practice and patient safety (Macgregor and Roberts) PPC-37
- "Medical Internet" resources and implications for future practice (Zuberi) PPC-23
- Medication reconciliation—Safer healthcare now! (Etchells) PPC-31
- Medication use and medication management standards (Taber) AGM-28
- Medication utilization rates after acute myocardial infarction in a cardiac rehabilitation population (Bucci and Oh) PPC-53
- Meeting the challenges of medication reconciliation in elective surgery patients: Verify, clarify, and reconcile (Carvalho) PPC-35
- Methodological issues in critical care clinical trials (Scales and others) PPC-45
- MOXXI project: Linking pharmacists, physicians and patients (Winslade) AGM-28
- National Pharmaceuticals Strategy (Nakagawa) AGM-23
- A new analgesic: Whole-plant-cannabis-based oral mucosal spray (Vanier) AGM-31
- Nouveautés en contraception (Ferreira) AGM-22
- Nouvelles approches d'anticoagulation en syndromes coronariens aigus (Pharand) AGM-25
- Osteoporosis and the elderly—The use of bisphosphonates and parathyroid hormone (Brown) PPC-29
- Palliative care medication kits (Harris and others) AGM-38
- Pharmaceutical care practice—What's new? (Raman-Wilms) PPC-26
- Pharmacist's role in medical mission to Guyana (Dole) PPC-35
- Pharmacoeconomic analysis of dalteparin vs. warfarin for the prevention of recurrent venous thromboembolic events in cancer patients (Dranitsaris and others) 48
- Pharmacokinetic predictors of treatment efficacy and adverse effects following mycophenolate therapy in lung transplant recipients (Ensom and others) PPC-49
- Pharmacy seamless care project—What do community pharmacists need from an acute care hospital to improve continuity of pharmaceutical care? (Cheng and others) PPC-57
- Physical compatibility of pantoprazole (PANTO® IV) with 36 medications during y-site simulation (Walker and others) AGM-37
- A practical approach to managing HIV drug interactions (Kelly) PPC-32
- Practical considerations with glargine insulin (Halapy) PPC-25
- Practical tips in stroke management (Mysak) PPC-27
- A prospective randomized study of 4% citrate vs. heparin for the prevention of bacteremia and thrombosis in patients with hemodialysis catheters (Dojcinovic and others) PPC-62
- Racism in the health care system: Uncovering bias and developing cultural competency skills for pharmacists (Choudhury) PPC-27
- Randomized evaluation of patient medication teaching by videotape in a cardiac care unit (Sidhu and others) 49
- Recruiting, training and evaluating pharmacists using key competencies (Tscheng and Gavura) PPC-58
- Respiratory fluoroquinolones for community-acquired pneumonia: Safety considerations (Carle) AGM-31
- A retrospective comparison of medication regimen complexity in renal transplant recipients receiving calcineurin inhibitors (Zuberi and others) AGM-39
- A retrospective comparison of variable concentrations versus standardized concentrations on 24-hour drug infusion volumes in a paediatric intensive care unit (Vaillancourt and others) AGM-40
- Retrospective methods of measuring practice change of pharmacists in continuing education (Ho and Winkelbauer) PPC-60
- Review of articles that will change your practice (Schuster) AGM-23
- Review of articles that will change your practice (Wilbur) PPC-43
- Revue de la douleur neuropathique (Bouchard) AGM-21
- The RIPPLE effect: An introduction to evidence-based healthcare (Arbo and Tejani) 47
- Risk assessment of medications in a pharmacy clean room (Dewhurst and others) PPC-63
- Risks and benefits of atypical antipsychotics in the elderly (Ibrahim) PPC-30
- The role of ipratropium in combination with tiotropium (Bayliff) PPC-24
- Role of the pharmacist in a lipid clinic (Semchuk) PPC-33
- The role of the pharmacist in cardiac rehab (Jorgenson) PPC-34
- Run for it! A rookie candidate's federal election experience (Graham) AGM-19
- Seizures associated with fluoroquinolones: A series of case reports (Shortridge and others) PPC-55
- Selection of a preferred proton pump inhibitor in the Canadian Forces: A drug use evaluation (Ma and others) PPC-52
- Self-management support: A pharmacist's journey from "sage on the stage" to "guide on the side" (Chong) PPC-42
- Silk purses out of sows' ears: Turning your leftover projects and posters into real publications (Ensom) AGM-26
- Stability of bortezomib vials reconstituted with 0.9% sodium chloride at 4°C and room temperature (23°C) (Walker and others) PPC-62
- Stability of naloxone stored in aqueous diluents in syringes at 4°C and room temperature (23°C) (Walker and others) PPC-62
- Standardized methods for measuring drug use: Making cents of the data! (Thirion and others) AGM-27
- Successful treatment to guideline recommended LDL-cholesterol targets in heart transplant recipients (Pearson and others) PPC-64
- Suspected drug interaction between clozapine and clarithromycin resulting in prolonged hospitalization (Loder and Lamoure) PPC-50
- Systematic protocol for managing drug information requests (Ho and Tscheng) PPC-61
- A systematic review of the risk of acquired protein C resistance in women taking third-generation over second-generation combination oral contraceptives (Ng) PPC-51
- The systemic overview of the relative benefits and risks of insulin sliding scale dosing regimen in stable patients with type 2 diabetes in hospitals (Shin) PPC-56
- Testing the utility of a patient medication record in chronic pain patients (Ng and others) PPC-57
- Thrombocytopenie induite par l'héparine : mythe ou réalité? (Williamson) AGM-30
- Trastuzumab therapy for early breast cancer (Charbonneau) PPC-41
- Tuberculosis (TB)—Emerging issues in pharmaceutical care (Chin) AGM-25
- Update on pediatric immunizations (Tjon) PPC-44
- The use of benzodiazepines for insomnia in older adults: Effect of group education on readiness to change and knowledge (Leung and others) PPC-50
- Use of concept maps to enhance learning within a traditional model of practice-based pharmacy education (Zuberi) AGM-40
- The use of proton pump inhibitors for stress ulcer prophylaxis in critical care: A systematic review (Arbo and Tejani) PPC-52
- Use of recombinant factor VIIa in critically ill patients (Perreault) PPC-45
- Use of the patient medication list to ensure continuity of care for elective surgery patients (Saleemi) PPC-51
- Using acute myocardial infarction (AMI) guidelines to improve the care of your patients: Taking evidence to the bedside (Thompson) PPC-29
- Ventilator-associated pneumonia (Chant) PPV-42
- What is new in contraception? (Ferreira) AGM-20
- What is USP Chapter <797> and how do I implement it? (Bornstein) PPC-26
- What strategies can pharmacists use to effectively impact prescribing practices? An evidence-based review (Martin) PPC-36
- Accreditation**
- Medication use and medication management standards (Taber) (Abs) AGM-28
- ACE inhibitors** See **Angiotensin-converting enzyme inhibitors**
- Acetylcholinesterase inhibitors** See **Cholinesterase inhibitors**
- Acid suppressive therapy** See **Antacids**
- Acinetobacter infections**
- In vitro modeling of IV meropenem [500 mg q 6h vs. 1 g q8h] in acinetobacter bacteraemia (Marchesano and others) (Abs) PPC-64
- Activated protein C resistance**
- A systematic review of the risk of acquired protein C resistance in women taking third-generation over second-generation combination oral contraceptives (Ng) (Abs) PPC-51

### **Administration, oral**

Reversal of overanticoagulation with vitamin K<sub>1</sub>: A plea for oral administration (Vanier and Ngo) (A) 125

### **Adolescent**

Practice spotlight: Natalie Dayneka (PP) 275

### **Adrenergic beta-antagonists**

2006 recommendations of the Canadian Hypertension Education Program: Sound bite version (Canadian Hypertension Education Program) (PP) 148

Medication utilization rates after acute myocardial infarction in a cardiac rehabilitation population (Bucci and Oh) (Abs) PPC-53

The use of ACE inhibitors,  $\beta$ -blockers, and warfarin in congestive heart failure: A community hospital study (Kwan and others) (A) 251

### **Adult**

Implementation of an insulin protocol in adult critically ill patients (Wynne and others) (Abs) PPC-51

### **Adverse drug reaction reporting systems**

Learning from medication incident data: The role of the Canadian Medication Incident Reporting and Prevention System (CMIRPS) (Hunt and others) (Abs) PPC-31

Medication error events in Ontario acute care hospitals (Marshman and others) (A) 243

Medication safety alerts (Greenall and Senders) (PP) 34

Monitoring and reporting adverse drug reactions in India: Initiatives and contributions from pharmacists (Jose and Rao) (L) 155

Perceptions of patients and health care professionals about factors contributing to medication errors and potential areas for improvement (Hartnell and others) (A) 177

Safe medication practices (Wells and Hyland) (PP) 273

### **Aged**

Comparison of a frail-friendly nomogram with physician-adjusted warfarin dosing for prophylaxis after orthopedic surgery on a geriatric rehabilitation unit (Bowles and Freter) (Abs) 49

Evaluation of a comprehensive medication review program in urban senior centers (Chang and O'Connell) (Abs) PPC-53

Osteoporosis and the elderly—The use of bisphosphonates and parathyroid hormone (Brown) (Abs) PPC-29

### **AIDS**

Practice spotlight: Natalie Dayneka (PP) 275

### **Alzheimer's disease**

Controversies in the management of dementia (Mills) (Abs) PPC-30

Diagnosis, causes, course and Rx of Alzheimer's disease (AD) (Gauthier) (Abs) AGM-23

### **American Society of Health-System Pharmacists**

Recognizing excellence in hospital pharmacy: Two international partners join the ranks of CSHP's honorary members (SN) 222

### **Aminoglycosides**

Infective endocarditis—New guidelines and old questions (Dresser and Dan) (Abs) PPC-39

### **Amiodarone**

Carbamazepine toxicity related to amiodarone use prior to cardiac surgery (Methot and others) (Abs) PPC-55

Ibutilide pretreatment to facilitate cardioversion of refractory atrial fibrillation in a patient with morbid obesity (Friesen and Ducas) (CR) 201

### **Analgesia, epidural**

Failure mode effects analysis of the pharmacy preparation of epidural syringes (Vaillancourt and others) (Abs) AGM-40

### **Analgesics**

Medication safety alerts (Seki and Turner) (PP) 152

### **Analyze-ERR See Software**

### **Anemia**

The ABCs of RBCs: An interactive talk about anemia in chronic kidney disease (Ng and Ong) (Abs) PPC-37

The development of a prediction tool for chemotherapy-induced anemia in breast cancer patients receiving adjuvant chemotherapy (Dranitsaris and others) (Abs) 47, 48

### **Angiotensin-converting enzyme inhibitors**

2006 recommendations of the Canadian Hypertension Education Program: Sound bite version (Canadian Hypertension Education Program) (PP) 148

ACEI versus ARB in high-risk vascular patients (Pickering and Semchuk) (Abs) PPC-33

Medication utilization rates after acute myocardial infarction in a cardiac rehabilitation population (Bucci and Oh) (Abs) PPC-53

The use of ACE inhibitors,  $\beta$ -blockers, and warfarin in congestive heart failure: A community hospital study (Kwan and others) (A) 251

### **Angiotensin II type 1 receptor blockers**

2006 recommendations of the Canadian Hypertension Education Program: Sound bite version (Canadian Hypertension Education Program) (PP) 148

ACEI versus ARB in high-risk vascular patients (Pickering and Semchuk) (Abs) PPC-33

### **Annual General Meeting See Congresses**

### **Antacids**

Acid suppressive therapy use on an inpatient internal medicine service (Pham and others) (Abs) AGM-34

### **Anti-arrhythmia agents**

Development of a strategy for safe dofetilide prescribing and monitoring (Rebellato and others) (Abs) PPC-58

Ibutilide pretreatment to facilitate cardioversion of refractory atrial fibrillation in a patient with morbid obesity (Friesen and Ducas) (CR) 201

### **Anti-bacterial agents**

Antibiotic consumption in populations: How does a North American jurisdiction compare with Europe? (Marra) (Abs) 48

Inadequate empiric antibiotic therapy: Incidence and in-hospital mortality among critically-ill and solid-organ transplant patients (Hamandi and others) (Abs) AGM-39

### **Antibiotics See Anti-bacterial agents**

### **Anticholesteremic agents**

Medication utilization rates after acute myocardial infarction in a cardiac rehabilitation population (Bucci and Oh) (Abs) PPC-53

Successful treatment to guideline recommended LDL-cholesterol targets in heart transplant recipients (Pearson and others) (Abs) PPC-64

### **Anticoagulants**

Approach to anticoagulation in acute coronary syndromes (Pharand) (Abs) AGM-29

The cost-effectiveness of patient self-managed versus physician-managed oral anticoagulation: A Bayesian approach (Sunderji and Marra) (Abs) 49

Nouvelles approches d'anticoagulation en syndromes coronariens aigus (Pharand) (Abs) AGM-25

### **Antihypertensive agents**

2006 recommendations of the Canadian Hypertension Education Program: Sound bite version (Canadian Hypertension Education Program) (PP) 148

### **Anti-infective agents**

Infective endocarditis—New guidelines and old questions (Dresser and Dan) (Abs) PPC-39

Standardized methods for measuring drug use: Making cents of the data! (Thirion and others) (Abs) AGM-27

### **Antimicrobial drug resistance See Drug resistance, microbial**

### **Antineoplastic agents**

Challenges of NIOSH guidelines for pharmacy (Bornstein) (Abs) PPC-43

Trastuzumab therapy for early breast cancer (Charbonneau) (Abs) PPC-41

### **Antineoplastic agents, phytogetic**

Irinotecan stability in vials following puncture when stored at 23°C or 4°C (Walker and others) (Abs) AGM-36

### **Antipsychotic agents**

Management of acute agitation and delirium: Are atypical antipsychotics just along for the ride? (Corrigan) (Abs) AGM-21

Risks and benefits of atypical antipsychotics in the elderly (Ibrahim) (Abs) PPC-30

### **Antiresorptive agents See Bone density conservation agents**

### **Antiretroviral agents**

A practical approach to managing HIV drug interactions (Kelly) (Abs) PPC-32

### **Antispasticity agents See Muscle relaxants, central**

### **Antithrombins**

A drug use evaluation comparing bivalirudin and the combination of heparin plus eptifibatide in elective percutaneous coronary intervention (Slagel and others) (Abs) AGM-34

### **Antiviral agents**

Avian influenza A (bird flu): Is the threat real? (Dib and Abdulmohsin) (L) 85

### **Aromatase inhibitors**

The evaluation and implementation of a process to identify patients eligible for an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone sensitive breast cancer patients in Newfoundland and Labrador (NL) (McCarthy and others) (Abs) AGM-35

### **Asociación Mexicana de Farmacéuticos de Hospital**

Recognizing excellence in hospital pharmacy: Two international partners join the ranks of CSHP's honorary members (SN) 222



## Aspirin

ASA resistance: A laboratory or clinical phenomenon? (Nagge) (Abs) PPC-26  
Medication utilization rates after acute myocardial infarction in a cardiac rehabilitation population (Bucci and Oh) (Abs) PPC-53

## Atrial fibrillation

Atrial fibrillation—Shocking new discoveries (Kertland) (Abs) PPC-32  
Ibutilide pretreatment to facilitate cardioversion of refractory atrial fibrillation in a patient with morbid obesity (Friesen and Ducas) (CR) 201

## Attitude of health personnel

Perceptions of patients and health care professionals about factors contributing to medication errors and potential areas for improvement (Hartnell and others) (A) 177

## Automatic data processing

Safe medication practices (Wells and Hyland) (PP) 273

## Avian influenza See Influenza in birds

## Awards and prizes

2006/2007 Awards Program (SN) 287  
Awards presentations at PPC 2006 (SN) 104  
Awards presentations at the 2006 Professional Practice Conference (SN) 46  
Distinguished Service Award 2005/2006, presented by Janssen-Ortho Inc: Linda Poloway (SN) 98  
Hospital Pharmacy Student Award 2005/2006: Justin Lee (SN) 102  
Isabel E Stauffer Meritorious Service Award 2005/2006, presented by Pharmaceutical Partners of Canada: Susan Poulin (SN) 99  
New Hospital Pharmacy Practitioner Award 2005/2006, presented by Sandoz Canada Inc  
Dawn Dalen (SN) 100  
Gloria Tsang (SN) 101  
Pfizer Residency Award Winners 2005 (SN) 103

Tribute to the appraisers of the 2005/2006 Awards Program (SN) 45

## Azimilide See Anti-arrhythmia agents

## Baclofen

Stopping medications in complex continuing care: The example of baclofen and dantrolene (Farrell and others) (A) 264

## Bacteremia

A prospective randomized study of 4% citrate vs. heparin for the prevention of bacteremia and thrombosis in patients with hemodialysis catheters (Dojcinovic and others) (Abs) PPC-62

## Bar codes See Automatic data processing

## Benzimidazoles

Physical compatibility of pantoprazole (PANTO® IV) with 36 medications during y-site simulation (Walker and others) (Abs) AGM-37

## Benzodiazepines

A description of the pharmacological management of acutely agitated patients in a psychiatric emergency department (Cheung and Chaiet) (Abs) PPC-59

The use of benzodiazepines for insomnia in older adults: Effect of group education on readiness to change and knowledge (Leung and others) (Abs) PPC-50

## Beta-blockers See Adrenergic beta-antagonists

## Bisphosphonates See Diphosphonates

## Bivalirudin See Antithrombins

## Blood dyscrasias See Paraproteinemias

## Bone density

Measuring the impact of pharmacist intervention: Results of patient education about osteoporosis after fragility fracture (Ho and others) (A) 184

## Bone density conservation agents

Measuring the impact of pharmacist intervention: Results of patient education about osteoporosis after fragility fracture (Ho and others) (A) 184

## Book reviews

*Pharmacist Disease Management: Diabetes*. 3rd edition. American Pharmacists Association (Cornish) 83  
*Pharmacy Technician Certification Review and Practice Exam*. 2nd edition. Fred LY, editor (Quinn) 83  
*Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine*. 2nd edition. Kowalsky RJ, Falen SW (Cornelissen and Kersemans) 154

## Boronic acids

Stability of bortezomib vials reconstituted with 0.9% sodium chloride at 4°C and room temperature (23°C) (Walker and others) (Abs) PPC-62

## Bortezomib See Boronic acids

## Breast neoplasms

The development of a prediction tool for chemotherapy-induced anemia in breast cancer patients receiving adjuvant chemotherapy (Dranitsaris and others) (Abs) 47, 48

The evaluation and implementation of a process to identify patients eligible for an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone sensitive breast cancer patients in Newfoundland and Labrador (NL) (McCarthy and others) (Abs) AGM-35

Trastuzumab therapy for early breast cancer (Charbonneau) (Abs) PPC-41

## British Columbia

Antibiotic consumption in populations: How does a North American jurisdiction compare with Europe? (Marra) (Abs) 48

## Bronchodilator agents

The role of ipratropium in combination with tiotropium (Bayliff) (Abs) PPC-24

## Calcineurin

A retrospective comparison of medication regimen complexity in renal transplant recipients receiving calcineurin inhibitors (Zuberi and others) (Abs) AGM-39

## Calcium

Measuring the impact of pharmacist intervention: Results of patient education about osteoporosis after fragility fracture (Ho and others) (A) 184

## Calcium channel blockers

2006 recommendations of the Canadian Hypertension Education Program: Sound bite version (Canadian Hypertension Education Program) (PP) 148

## Canadian Association of Pharmacy Students and Interns

A missed exit ramp, an unforgettable year / Une bretelle d'accès manquée, une année réussie (Roy) (EDR) 52 / 53

## Canadian Council on Health Services Accreditation

Medication use and medication management standards (Taber) (Abs) AGM-28

## Canadian Hospital Pharmacy Residency Board

Competency-based accreditation standards for residency training (Woloschuk) (L) 214

## Canadian Hypertension Education Program

2006 recommendations of the Canadian Hypertension Education Program: Sound bite version (Canadian Hypertension Education Program) (PP) 148

## Canadian Journal of Hospital Pharmacy

Editorial relationships: CSHP and *CJHP* / Relations éditoriales : SCPH et *JCPH* (Dupuis) (E) 171 / 175

Instructions to authors (SN) 50, 223

A motivation letter / Une lettre de motivation (Ensom) (E) 61 / 65

A time of transition / Un temps de transition (Walker) (E) 4 / 6

Value of peer review in publishing / La valeur des publications évaluées par les pairs (Vaillancourt) (E) 113 / 117

## Canadian Medication Incident Reporting and Prevention System (CMIRPS) See Adverse drug reaction reporting systems

## Canadian Society of Hospital Pharmacists

2006/2007 Awards Program (SN) 287

Are you a "leader-in-waiting"? / Êtes-vous un «leader en puissance»? (Bornstein) (SN) 225 / 226

CSHP Fellows PPC-66

CSHP position statement on pharmacist as head of hospital pharmacy (Dayneka) (L) 88

(Gray and others) (L) 86

(Johnson) (L) 87

Response from CSHP executive (Letwin and others) (L) 88

CSHP R&E Foundation benefits from generous support of AstraZeneca (SN) 45

Editorial relationships: CSHP and *CJHP* / Relations éditoriales : SCPH et *JCPH* (Dupuis) (E) 171 / 175

A missed exit ramp, an unforgettable year / Une bretelle d'accès manquée, une année réussie (Roy) (EDR) 52 / 53

Oh, tous ces endroits où vous irez! / Oh, the places you'll go! (Letwin) (POR) 227 / 228

Potential impact of implementing an entry-level Doctor of Pharmacy degree in Canada: 2005 update (Canadian Society of Hospital Pharmacists) (Pos) 37

Recognizing excellence in hospital pharmacy: Two international partners join the ranks of CSHP's honorary members (SN) 222

A wrinkle in time / Un signe du temps (Musing) (POR) 288 / 289

Souvenirs heureux / Looking back with pride (Vaillancourt) (POR) 163 / 164

Tribute to the appraisers of the 2005/2006 Awards Program (SN) 45

## Cannabidiol

Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) buccal spray: Experience in one patient (Min and others) (Abs) PPC-53



A new analgesic: Whole-plant-cannabis-based oral mucosal spray (Vanier) (Abs) AGM-31

### **Carbamazepine**

Carbamazepine toxicity related to amiodarone use prior to cardiac surgery (Methot and others) (Abs) PPC-55

### **Carbapenems**

Management of hospital-acquired pneumonia at a tertiary-care teaching hospital (Seto and others) (A) 69

### **Cardiovascular diseases**

ACEI versus ARB in high-risk vascular patients (Pickering and Semchuk) (Abs) PPC-33

The alphabet soup of cardiac devices (Chiu) (Abs) PPC-33

Approach to anticoagulation in acute coronary syndromes (Pharand) (Abs) AGM-29

Cardiac diagnostic testing—A primer for pharmacists (Pearson) (Abs) PPC-24

Cardiovascular prevention and therapy: The mountain population report card—How are we doing at home? (Labelle-Stimac and others) (Abs) AGM-39

Nouvelles approches d'anticoagulation en syndromes coronariens aigus (Pharand) (Abs) AGM-25

The role of the pharmacist in cardiac rehab (Jorgenson) (Abs) PPC-34

### **Ceftazidime**

Management of hospital-acquired pneumonia at a tertiary-care teaching hospital (Seto and others) (A) 69

### **Cerebrovascular accident**

Practical tips in stroke management (Mysak) (Abs) PPC-27

### **Chemotherapy, adjuvant**

The development of a prediction tool for chemotherapy-induced anemia in breast cancer patients receiving adjuvant chemotherapy (Dranitsaris and others) (Abs) 47, 48

### **Child**

Drug toxicity, pharmacovigilance and tailored therapy (Stenton) (Abs) PPC-40

A drug use evaluation of milrinone in pediatric critical care patients (Bishara and others) (Abs) PPC-57

Practice spotlight: Natalie Dayneka (PP) 275

A retrospective comparison of variable concentrations versus standardized concentrations on 24-hour drug infusion volumes in a paediatric intensive care unit (Vaillancourt and others) (Abs) AGM-40

### **Cholinesterase inhibitors**

Controversies in the management of dementia (Mills) (Abs) PPC-30

**Chronic obstructive pulmonary disease** See **Pulmonary disease, chronic obstructive**

**Chronic pain** See **Pain, intractable**

### **Ciprofloxacin**

Management of hospital-acquired pneumonia at a tertiary-care teaching hospital (Seto and others) (A) 69

### **Citrates**

A prospective randomized study of 4% citrate vs. heparin for the prevention of bacteremia and thrombosis in patients with hemodialysis catheters (Dojcinovic and others) (Abs) PPC-62

**CJHP** See **Canadian Journal of Hospital Pharmacy**

### **Clarithromycin**

Suspected drug interaction between clozapine and clarithromycin resulting in prolonged hospitalization (Loder and Lamoure) (Abs) PPC-50

**Clean rooms** See **Environment, controlled**

### **Clinical trial [publication type]**

Methodological issues in critical care clinical trials (Scales and others) (Abs) PPC-45

### **Clostridium difficile**

Standardized methods for measuring drug use: Making cents of the data! (Thirion and others) (Abs) AGM-27

### **Clozapine**

Suspected drug interaction between clozapine and clarithromycin resulting in prolonged hospitalization (Loder and Lamoure) (Abs) PPC-50

### **Coagulants**

Use of recombinant factor VIIa in critically ill patients (Perreault) (Abs) PPC-45

### **Colitis, ulcerative**

Infliximab: New role in ulcerative colitis (Pham) (Abs) AGM-20

Infliximab : nouveau rôle dans le traitement de la colite ulcéreuse (Pham) (Abs) AGM-22

### **Communicable diseases**

Appel aux armes! Une mise à jour sur les pratiques contre l'invasion des nouvelles maladies infectieuses (Thirion) (Abs) AGM-21

Holding the line! Updates on emerging infections (Thirion) (Abs) AGM-19

### **Community-acquired infections**

Clinical practice guidelines for community-acquired pneumonia: An investigation into creation, characteristics, quality and compliance with production guides (Jewesson and Gill) (Abs) PPC-60

Community-acquired MRSA: An emerging pathogen (Evans) (Abs) PPC-38

Respiratory fluoroquinolones for community-acquired pneumonia: Safety considerations (Carle) (Abs) AGM-31

**Compatibility, drug** See **Drug incompatibility**

**Conferences** See **Congresses**

### **Confidentiality**

The confidentiality of community pharmacy records is at risk: A survey of designated pharmacy managers (Ford and others) (Abs) PPC-61

### **Conflict of interest**

Ethical conduct—Point and counterpoint (Ensom and Hall) (Abs) PPC-44

### **Congresses**

Awards presentations at PPC 2006 (SN) 104

Awards presentations at the 2006 Professional Practice Conference (SN) 46

Enseigner et apprendre / Teach and be taught (Letwin) (POR) 55 / 56  
Oh, tous ces endroits où vous irez! / Oh, the places you'll go! (Letwin) (POR) 227 / 228

### **Continuity of patient care**

Bridging theory to practice: Practical considerations for implementing medication reconciliation strategies (Fernandes) (Abs) AGM-29

Implantation d'un programme de continuité de soins pharmaceutiques pour la clientèle atteinte de maladies respiratoires (Beauchesne and others) (Abs) AGM-35

Implementation of medication reconciliation in a rehabilitation/complex continuing care facility (Karakolis and others) (Abs) PPC-55

Meeting the challenges of medication reconciliation in elective surgery patients: Verify, clarify, and reconcile (Carvalho) (Abs) PPC-35

Pharmacy seamless care project—What do community pharmacists need from an acute care hospital to improve continuity of pharmaceutical care? (Cheng and others) (Abs) PPC-57

Use of the patient medication list to ensure continuity of care for elective surgery patients (Saleemi) (Abs) PPC-51

### **Contraceptive agents**

Nouveautés en contraception (Ferreira) (Abs) AGM-22

What is new in contraception? (Ferreira) (Abs) AGM-20

### **Contraceptive devices**

Nouveautés en contraception (Ferreira) (Abs) AGM-22

What is new in contraception? (Ferreira) (Abs) AGM-20

### **Contraceptives, oral**

A systematic review of the risk of acquired protein C resistance in women taking third-generation over second-generation combination oral contraceptives (Ng) (Abs) PPC-51

### **Cost-benefit analysis**

The cost-effectiveness of patient self-managed versus physician-managed oral anticoagulation: A Bayesian approach (Sunderji and Marra) (Abs) 49

Medication safety alerts (Greenall) (PP) 81

**Cost-effectiveness** See **Cost-benefit analysis**

### **Costs and cost analysis**

Pharmacoeconomic analysis of dalteparin vs. warfarin for the prevention of recurrent venous thromboembolic events in cancer patients (Dranitsaris and others) (Abs) 48

Understanding a patient's approach to medication use: An aid to tailoring medication information (Bajcar) (A) 119

### **Critical care**

A drug use evaluation of milrinone in pediatric critical care patients (Bishara and others) (Abs) PPC-57

Implementation of an insulin protocol in adult critically ill patients (Wynne and others) (Abs) PPC-51

Methodological issues in critical care clinical trials (Scales and others) (Abs) PPC-45

The use of proton pump inhibitors for stress ulcer prophylaxis in critical care: A systematic review (Arbo and Tejani) (Abs) PPC-52

### **Critical illness**

Inadequate empiric antibiotic therapy: Incidence and in-hospital mortality among critically-ill and solid-organ transplant patients (Hamandi and others) (Abs) AGM-39

### **Cross infection**

Management of hospital-acquired pneumonia at a tertiary-care teaching hospital (Seto and others) (A) 69

**CSHP** See **Canadian Society of Hospital Pharmacists**

### **Cultural diversity**

Exploring the impact of cultural differences on hospital pharmacists (Laroche) (Abs) PPC-23



## Curriculum

- Entry-level doctor of pharmacy program: The Canadian debate / Programme de doctorat professionnel de premier cycle en pharmacie : débat canadien (Hindmarsh) (E) 9 / 12
- Pharmacy residents developing teaching skills during the pharmacy practice residency program: A closer look at the issue (Gerber) (A) 14
- Position paper on the role of hospital residency programs in clinical training and professional development in the era of the proposed entry-level Doctor of Pharmacy program (Executive of the Hospital Pharmacy Residency Forum of Ontario) (Pos) 210
- Potential impact of implementing an entry-level Doctor of Pharmacy degree in Canada: 2005 update (Canadian Society of Hospital Pharmacists) (Pos) 37

## Cyclosporine

- Cyclosporine absorption profiling and its limited sampling strategies in lung transplant recipients (Ensom and others) (Abs) PPC-49

## Cystic fibrosis

- Night blindness secondary to vitamin A deficiency in a patient with cystic fibrosis and short-gut syndrome (Leung and others) (CR) 74

## Dalteparin

- Pharmacoeconomic analysis of dalteparin vs. warfarin for the prevention of recurrent venous thromboembolic events in cancer patients (Dranitsaris and others) (Abs) 48

## Dantrolene

- Stopping medications in complex continuing care: The example of baclofen and dantrolene (Farrell and others) (A) 264

## Defibrotide See Fibrinolytic agents

## Delirium

- Management of acute agitation and delirium: Are atypical antipsychotics just along for the ride? (Corrigan) (Abs) AGM-21

## Dementia

- Controversies in the management of dementia (Mills) (Abs) PPC-30
- Risks and benefits of atypical antipsychotics in the elderly (Ibrahim) (Abs) PPC-30

## Diabetes mellitus

- In-hospital management of diabetes (Gordon) (Abs) PPC-28
- Pharmacist Disease Management: Diabetes*. 3rd edition. American Pharmacists Association (Cornish) (BR) 83

## Diabetes mellitus, type 2

- Adherence to Canadian Diabetes Association Clinical Practice Guidelines in an outpatient diabetes education centre (Crossman and others) (Abs) AGM-36
- The systemic overview of the relative benefits and risks of insulin sliding scale dosing regimen in stable patients with type 2 diabetes in hospitals (Shin) (Abs) PPC-56

## Diagnosis

- Highs, lows, & everything in between: Interpreting liver & kidney function in the acute & chronic setting (Burry and Ledger) (Abs) PPC-28

## Diagnostic techniques, cardiovascular

- Cardiac diagnostic testing—A primer for pharmacists (Pearson) (Abs) PPC-24

## Diphosphonates

- Osteoporosis and the elderly—The use of bisphosphonates and parathyroid hormone (Brown) (Abs) PPC-29

## Disaster planning

- Disaster planning: Lessons learned from Hurricane Katrina (McCrory, Jr.) (Abs) AGM-33

## Diuretics, thiazide

- 2006 recommendations of the Canadian Hypertension Education Program: Sound bite version (Canadian Hypertension Education Program) (PP) 148

## Dofetilide See Anti-arrhythmia agents

## Drug compatibility See Drug incompatibility

## Drug compounding

- What is USP Chapter <797> and how do I implement it? (Bornstein) (Abs) PPC-26

## Drug evaluation

- Jongler avec les chiffres : comprendre les résultats des études (Lévesquez) (Abs) AGM-30

## Drug incompatibility

- Physical compatibility of pantoprazole (PANTO® IV) with 36 medications during y-site simulation (Walker and others) (Abs) AGM-37

## Drug industry

- Ethical conduct—Point and counterpoint (Ensom and Hall) (Abs) PPC-44

## Drug Information and Research Centre See Drug information services

## Drug information services

- Systematic protocol for managing drug information requests (Ho and Tscheng) (Abs) PPC-61

## Drug interactions

- Carbamazepine toxicity related to amiodarone use prior to cardiac surgery (Methot and others) (Abs) PPC-55
- Lowering of serum valproic acid levels during concomitant therapy with meropenem: A clinically relevant drug interaction (Trope and others) (Abs) PPC-65
- A practical approach to managing HIV drug interactions (Kelly) (Abs) PPC-32
- Suspected drug interaction between clozapine and clarithromycin resulting in prolonged hospitalization (Loder and Lamoure) (Abs) PPC-50

## Drug labelling

- Safe medication practices (Wells and Hyland) (PP) 273

## Drug monitoring

- Cyclosporine absorption profiling and its limited sampling strategies in lung transplant recipients (Ensom and others) (Abs) PPC-49
- Development of a strategy for safe dofetilide prescribing and monitoring (Rebellato and others) (Abs) PPC-58
- Drug metabolizing enzymes: Putting pharmacogenetics to practice (Ensom) (Abs) PPC-60
- Limited sampling strategies for mycophenolic acid area-under-the-concentration-time curve in lung transplant recipients (Ensom and others) (Abs) PPC-48
- Stopping medications in complex continuing care: The example of baclofen and dantrolene (Farrell and others) (A) 264

## Drug resistance, microbial

- Do bugs need drugs? A community program for wise use of antibiotics (Blondel-Hill and Fryters) (Abs) PPC-34
- Management of hospital-acquired pneumonia at a tertiary-care teaching hospital (Seto and others) (A) 69

## Drug stability

- Irinotecan stability in vials following puncture when stored at 23°C or 4°C (Walker and others) (Abs) AGM-36
- Stability of bortezomib vials reconstituted with 0.9% sodium chloride at 4°C and room temperature (23°C) (Walker and others) (Abs) PPC-62
- Stability of naloxone stored in aqueous diluents in syringes at 4°C and room temperature (23°C) (Walker and others) (Abs) PPC-62
- Stability of nitrofurantoin in extemporaneously compounded suspensions (Ensom and Decarie) (A) 29
- Stability of sulfasalazine oral suspension (Lingertat-Walsh and others) (A) 194

## Drug utilization

- Acid suppressive therapy use on an inpatient internal medicine service (Pham and others) (Abs) AGM-34
- Antibiotic consumption in populations: How does a North American jurisdiction compare with Europe? (Marra) (Abs) 48
- The effectiveness of interventions designed to reduce meperidine use in hospital (Groenstege) (Abs) PPC-56
- Medication utilization rates after acute myocardial infarction in a cardiac rehabilitation population (Bucci and Oh) (Abs) PPC-53
- Selection of a preferred proton pump inhibitor in the Canadian Forces: A drug use evaluation (Ma and others) (Abs) PPC-52
- Standardized methods for measuring drug use: Making cents of the data! (Thirion and others) (Abs) AGM-27
- Stopping medications in complex continuing care: The example of baclofen and dantrolene (Farrell and others) (A) 264
- The use of ACE inhibitors,  $\beta$ -blockers, and warfarin in congestive heart failure: A community hospital study (Kwan and others) (A) 251

## Economics, pharmaceutical

- National Pharmaceuticals Strategy (Nakagawa) (Abs) AGM-23

## Editorials

- Editorial relationships: CSHP and *CJHP* / Relations éditoriales : SCPH et *JCPH* (Dupuis) 171 / 175
- Entry-level doctor of pharmacy program: The Canadian debate / Programme de doctorat professionnel de premier cycle en pharmacie : débat canadien (Hindmarsh) 9 / 12
- A motivation letter / Une lettre de motivation (Ensom) 61 / 65
- Pharmacist? What pharmacist? / Pharmacien? Quel pharmacien? (Tisdale) 235 / 239
- A time of transition / Un temps de transition (Walker) 4 / 6
- Value of peer review in publishing / La valeur des publications évaluées par les pairs (Vaillancourt) 113 / 117

## Education, pharmacy

- A Canadian-trained pharmacist in the United States (Peeters) (L) 155



- Competency-based accreditation standards for residency training (Woloschuk) (L) 214
- Entry-level doctor of pharmacy program: The Canadian debate / Programme de doctorat professionnel de premier cycle en pharmacie : débat canadien (Hindmarsh) (E) 9 / 12
- Entry-level PharmD degree programs in Canada: Some facts and stakeholder opinions (Jewesson and others) (Abs) PPC-59
- The future of residency training in Canada (Woloschuk) (Abs) AGM-24
- Pharmacy residents developing teaching skills during the pharmacy practice residency program: A closer look at the issue (Gerber) (A) 14
- Position paper on the role of hospital residency programs in clinical training and professional development in the era of the proposed entry-level Doctor of Pharmacy program (Executive of the Hospital Pharmacy Residency Forum of Ontario) (Pos) 210
- Potential impact of implementing an entry-level Doctor of Pharmacy degree in Canada: 2005 update (Canadian Society of Hospital Pharmacists) (Pos) 37
- Use of concept maps to enhance learning within a traditional model of practice-based pharmacy education (Zuberi) (Abs) AGM-40
- Education, pharmacy, continuing**
- Development of an educational sabbatical program for pharmacists (Musing and others) (Abs) 47
- Retrospective methods of measuring practice change of pharmacists in continuing education (Ho and Winkelbauer) (Abs) PPC-60
- Electrical cardioversion** See **Electric countershock**
- Electric countershock**
- Ibutilide pretreatment to facilitate cardioversion of refractory atrial fibrillation in a patient with morbid obesity (Friesen and Ducas) (CR) 201
- Emergency services, psychiatric**
- A description of the pharmacological management of acutely agitated patients in a psychiatric emergency department (Cheung and Chaiet) (Abs) PPC-59
- Endocarditis**
- Infective endocarditis—New guidelines and old questions (Dresser and Dan) (Abs) PPC-39
- Enoxaparin**
- Approach to anticoagulation in acute coronary syndromes (Pharand) (Abs) AGM-29
- Impact of pharmacy intervention on venous thromboprophylaxis (Assaraf and others) (Abs) AGM-36
- Nouvelles approches d'anticoagulation en syndromes coronariens aigus (Pharand) (Abs) AGM-25
- Environment, controlled**
- Risk assessment of medications in a pharmacy clean room (Dewhurst and others) (Abs) PPC-63
- Eptifibatide** See **Fibrinolytic agents**
- Erythropoietin**
- The ABCs of RBCs: An interactive talk about anemia in chronic kidney disease (Ng and Ong) (Abs) PPC-37
- Etomidate**
- L'étomidate a-t-il une place dans nos chariots de réanimation? (Marquis) (Abs) AGM-32
- Europe**
- Antibiotic consumption in populations: How does a North American jurisdiction compare with Europe? (Marra) (Abs) 48
- Evidence-based medicine**
- Evidence and a regional drug formulary: The Fraser Health Authority experience (Tejani and others) (Abs) AGM-37
- Evidence-based medicine workshop—Appraising systematic reviews (Slavik) (Abs) AGM-26
- How to integrate evidence-based medicine into your daily practice: Help for the busy clinician (Arbo and Tejani) (Abs) PPC-36
- The RIPPLE effect: An introduction to evidence-based healthcare (Arbo and Tejani) (Abs) 47
- Using acute myocardial infarction (AMI) guidelines to improve the care of your patients: Taking evidence to the bedside (Thompson) (Abs) PPC-29
- What strategies can pharmacists use to effectively impact prescribing practices? An evidence-based review (Martin) (Abs) PPC-36
- Exocrine pancreatic insufficiency**
- Night blindness secondary to vitamin A deficiency in a patient with cystic fibrosis and short-gut syndrome (Leung and others) (CR) 74
- Fibrinolytic agents**
- Le défibrotide et la maladie hépatique veino-occlusive, vous connaissez? (Côté) (Abs) AGM-32
- A drug use evaluation comparing bivalirudin and the combination of heparin plus eptifibatide in elective percutaneous coronary intervention (Slagel and others) (Abs) AGM-34
- Practical tips in stroke management (Mysak) (Abs) PPC-27
- Fluoroquinolones**
- Respiratory fluoroquinolones for community-acquired pneumonia: Safety considerations (Carle) (Abs) AGM-31
- Seizures associated with fluoroquinolones: A series of case reports (Shortridge and others) (Abs) PPC-55
- Folic acid**
- Characteristics associated with adequate folic acid supplementation in a multicultural urban setting (Ferreira and others) (A) 22
- Fondaparinux** See **Anticoagulants**
- Formularies**
- Evidence and a regional drug formulary: The Fraser Health Authority experience (Tejani and others) (Abs) AGM-37
- Fractures, bone**
- Measuring the impact of pharmacist intervention: Results of patient education about osteoporosis after fragility fracture (Ho and others) (A) 184
- Frail elderly**
- Risks and benefits of atypical antipsychotics in the elderly (Ibrahim) (Abs) PPC-30
- Gastrointestinal agents**
- Infliximab: New role in ulcerative colitis (Pham) (Abs) AGM-20
- Infliximab : nouveau rôle dans le traitement de la colite ulcéreuse (Pham) (Abs) AGM-22
- Glargine insulin** See **Insulin**
- Guyana**
- Pharmacist's role in medical mission to Guyana (Dole) (Abs) PPC-35
- Haemophilus influenzae**
- Management of hospital-acquired pneumonia at a tertiary-care teaching hospital (Seto and others) (A) 69
- Health knowledge, attitudes, practice**
- Perceptions of patients and health care professionals about factors contributing to medication errors and potential areas for improvement (Hartnell and others) (A) 177
- Understanding a patient's approach to medication use: An aid to tailoring medication information (Bajcar) (A) 119
- Heart failure, congestive**
- The use of ACE inhibitors,  $\beta$ -blockers, and warfarin in congestive heart failure: A community hospital study (Kwan and others) (A) 251
- Heart transplantation**
- Successful treatment to guideline recommended LDL-cholesterol targets in heart transplant recipients (Pearson and others) (Abs) PPC-64
- Hemodialysis** See **Renal dialysis**
- Heparin**
- Approach to anticoagulation in acute coronary syndromes (Pharand) (Abs) AGM-29
- A drug use evaluation comparing bivalirudin and the combination of heparin plus eptifibatide in elective percutaneous coronary intervention (Slagel and others) (Abs) AGM-34
- Heparin-induced thrombocytopenia: Fact or fiction? (Williamson) (Abs) AGM-27
- Impact of pharmacy intervention on venous thromboprophylaxis (Assaraf and others) (Abs) AGM-36
- Nouvelles approches d'anticoagulation en syndromes coronariens aigus (Pharand) (Abs) AGM-25
- A prospective randomized study of 4% citrate vs. heparin for the prevention of bacteremia and thrombosis in patients with hemodialysis catheters (Dojcinovic and others) (Abs) PPC-62
- A retrospective evaluation of adherence to guidelines for prevention of thromboembolic events in general medical inpatients (Patel and others) (A) 258
- Thrombocytopenie induite par l'héparine : mythe ou réalité? (Williamson) (Abs) AGM-30
- Heparin, low-molecular-weight**
- Approach to anticoagulation in acute coronary syndromes (Pharand) (Abs) AGM-29
- Nouvelles approches d'anticoagulation en syndromes coronariens aigus (Pharand) (Abs) AGM-25
- Hepatic veins**
- Le défibrotide et la maladie hépatique veino-occlusive, vous connaissez? (Côté) (Abs) AGM-32





### **Hip fractures**

An evaluation of a multidisciplinary approach to the treatment of osteoporosis in patients following a low trauma hip fracture (Markowski and Richardson) (Abs) 48  
Measuring the impact of pharmacist intervention: Results of patient education about osteoporosis after fragility fracture (Ho and others) (A) 184

### **HIV**

A practical approach to managing HIV drug interactions (Kelly) (Abs) PPC-32  
Practice spotlight: Natalie Dayneka (PP) 275

### **Home care services**

Evaluation of clinical pharmacy services in the home care setting: A pharmacy pilot project (MacAulay and others) (Abs) AGM-35

### **Hospital administration**

CSHP position statement on pharmacist as head of hospital pharmacy (Dayneka) (L) 88  
(Gray and others) (L) 86  
(Johnson) (L) 87  
Response from CSHP executive (Letwin and others) (L) 88  
Un long chemin sinueux / The long and winding road (Musing) (POR) 107 / 108

### **Hospital mortality**

Inadequate empiric antibiotic therapy: Incidence and in-hospital mortality among critically-ill and solid-organ transplant patients (Hamandi and others) (Abs) AGM-39

### **Hospital Pharmacy Residency Forum of Ontario**

Position paper on the role of hospital residency programs in clinical training and professional development in the era of the proposed entry-level Doctor of Pharmacy program (Executive of the Hospital Pharmacy Residency Forum of Ontario) (Pos) 210

### **Hydroxymethylglutaryl-CoA reductase inhibitors**

Successful treatment to guideline recommended LDL-cholesterol targets in heart transplant recipients (Pearson and others) (Abs) PPC-64

### **Hyperglycemia**

In-hospital management of diabetes (Gordon) (Abs) PPC-28  
The systemic overview of the relative benefits and risks of insulin sliding scale dosing regimen in stable patients with type 2 diabetes in hospitals (Shin) (Abs) PPC-56

### **Hypertension**

2006 recommendations of the Canadian Hypertension Education Program: Sound bite version (Canadian Hypertension Education Program) (PP) 148

### **Hypoglycemia**

Practical considerations with glargine insulin (Halapy) (Abs) PPC-25  
The systemic overview of the relative benefits and risks of insulin sliding scale dosing regimen in stable patients with type 2 diabetes in hospitals (Shin) (Abs) PPC-56

### **Ibutilide** See **Anti-arrhythmia agents**

### **Immunization programs**

Update on pediatric immunizations (Tjon) (Abs) PPC-44

### **Implants** See **Prostheses and implants**

### **Insomnia** See **Sleep initiation and maintenance disorders**

### **India**

Monitoring and reporting adverse drug reactions in India: Initiatives and contributions from pharmacists (Jose and Rao) (L) 155

### **Infant, newborn**

Medication safety alerts (Greenall) (PP) 81

### **Infliximab** See **Gastrointestinal agents**

### **Influenza A virus**

Avian influenza A (bird flu): Is the threat real? (Dib and Abdulmohsin) (L) 85

### **Influenza in birds**

Avian influenza A (bird flu): Is the threat real? (Dib and Abdulmohsin) (L) 85

### **Information services**

"Medical Internet" resources and implications for future practice (Zuberi) (Abs) PPC-23

### **Injections, intravenous**

Traitement d'une extravasation de phénytoïne avec la phentolamine (Châteauevert and others) (CR) 76

### **INR** See **International normalized ratio**

### **Inservice training**

Development of a comprehensive training program for new pharmacist hires (Leblanc and Bhaloo) (Abs) PPC-64

### **Institute for Safe Medication Practices** See **Adverse drug reaction reporting systems**

### **Insulin**

Implementation of an insulin protocol in adult critically ill patients (Wynne and others) (Abs) PPC-51  
In-hospital management of diabetes (Gordon) (Abs) PPC-28  
Practical considerations with glargine insulin (Halapy) (Abs) PPC-25  
The systemic overview of the relative benefits and risks of insulin sliding scale dosing regimen in stable patients with type 2 diabetes in hospitals (Shin) (Abs) PPC-56

### **Intensive care**

A retrospective comparison of variable concentrations versus standardized concentrations on 24-hour drug infusion volumes in a paediatric intensive care unit (Vaillancourt and others) (Abs) AGM-40

### **Interactions, drug** See **Drug interactions**

### **International normalized ratio**

Comparison of a frail-friendly nomogram with physician-adjusted warfarin dosing for prophylaxis after orthopedic surgery on a geriatric rehabilitation unit (Bowles and Freter) (Abs) 49

Implementation and evaluation of a warfarin dosing service for rehabilitation medicine: Report from a pilot project (Chau and others) (A) 136

Reversal of overanticoagulation with vitamin K<sub>1</sub>: A plea for oral administration (Vanier and Ngo) (A) 125

### **Internet**

"Medical Internet" resources and implications for future practice (Zuberi) (Abs) PPC-23

### **Internship and residency**

Competency-based accreditation standards for residency training (Woloschuk) (L) 214

Pharmacy residents developing teaching skills during the pharmacy practice residency program: A closer look at the issue (Gerber) (A) 14

Position paper on the role of hospital residency programs in clinical training and professional development in the era of the proposed entry-level Doctor of Pharmacy program (Executive of the Hospital Pharmacy Residency Forum of Ontario) (Pos) 210

### **Ipratropium**

The role of ipratropium in combination with tiotropium (Bayliff) (Abs) PPC-24

### **Irinotecan** See **Antineoplastic agents, phytogetic**

### **ISMP Canada** See **Adverse drug reaction reporting systems**

### **Job satisfaction**

Racism in the health care system: Uncovering bias and developing cultural competency skills for pharmacists (Choudhury) (Abs) PPC-27

### **Kidney**

Highs, lows, & everything in between: Interpreting liver & kidney function in the acute & chronic setting (Burry and Ledger) (Abs) PPC-28

### **Kidney failure, chronic**

The ABCs of RBCs: An interactive talk about anemia in chronic kidney disease (Ng and Ong) (Abs) PPC-37

### **Kidney transplantation**

A retrospective comparison of medication regimen complexity in renal transplant recipients receiving calcineurin inhibitors (Zuberi and others) (Abs) AGM-39

### **Lamotrigine** See **Triazines**

### **Leadership**

Are you a "leader-in-waiting"? / Êtes-vous un «leader en puissance»? (Bornstein) (SN) 225 / 226

Coming attractions: Previews to leadership (Letwin and others) (Abs) AGM-24

### **Learning**

Use of concept maps to enhance learning within a traditional model of practice-based pharmacy education (Zuberi) (Abs) AGM-40

### **Letters**

Avian influenza A (bird flu): Is the threat real? (Dib and Abdulmohsin) 85  
A Canadian-trained pharmacist in the United States (Peeters) 155

Competency-based accreditation standards for residency training (Woloschuk) 214

CSHP position statement on pharmacist as head of hospital pharmacy (Dayneka) 88

(Gray and others) 86  
(Johnson) 87

Response from CSHP executive (Letwin and others) 88

Monitoring and reporting adverse drug reactions in India: Initiatives and contributions from pharmacists (Jose and Rao) 155

### **Levofloxacin** See **Ofloxacin**



## **Lifestyle**

2006 recommendations of the Canadian Hypertension Education Program: Sound bite version (Canadian Hypertension Education Program) (PP) 148

## **Lipids**

Role of the pharmacist in a lipid clinic (Semchuk) (Abs) PPC-33

## **Liver**

Highs, lows, & everything in between: Interpreting liver & kidney function in the acute & chronic setting (Burry and Ledger) (Abs) PPC-28

## **Loxapine**

A description of the pharmacological management of acutely agitated patients in a psychiatric emergency department (Cheung and Chaiet) (Abs) PPC-59

## **Lung transplantation**

Cyclosporine absorption profiling and its limited sampling strategies in lung transplant recipients (Ensom and others) (Abs) PPC-49

Genetic variation in UDP-glucuronosyltransferases and metabolism of mycophenolic acid in lung transplant recipients: A preliminary study (Ensom and others) (Abs) PPC-48

Limited sampling strategies for mycophenolic acid area-under-the-concentration-time curve in lung transplant recipients (Ensom and others) (Abs) PPC-48

Pharmacokinetic predictors of treatment efficacy and adverse effects following mycophenolate therapy in lung transplant recipients (Ensom and others) (Abs) PPC-49

## **Malaria**

IV quinine—Do you know how to get it? (Bubbar) (Abs) PPC-25

## **Medical missions, official**

Pharmacist's role in medical mission to Guyana (Dole) (Abs) PPC-35

## **Medical order entry systems**

Anatomy and physiology of CPOE—Patient safety issues (Ritchie) (Abs) PPC-46

The anatomy and physiology of CPOE (Barnett) (Abs) PPC-46

## **Medical records**

Testing the utility of a patient medication record in chronic pain patients (Ng and others) (Abs) PPC-57

## **Medical records systems, computerized**

The confidentiality of community pharmacy records is at risk: A survey of designated pharmacy managers (Ford and others) (Abs) PPC-61

## **Medication errors**

Anatomy and physiology of CPOE—Patient safety issues (Ritchie) (Abs) PPC-46

Bridging theory to practice: Practical considerations for implementing medication reconciliation strategies (Fernandes) (Abs) AGM-29

Drug-related hospitalization to a tertiary care internal medicine service: A prospective study (Samoy and others) (Abs) 47

Drug toxicity, pharmacovigilance and tailored therapy (Stenton) (Abs) PPC-40

Establishment of an admission medication reconciliation program (Guimont and others) (Abs) AGM-38

Implementation of a prohibited list of abbreviations in the David Thompson Health Region (Poloway) (Abs) AGM-40

Learning from medication incident data: The role of the Canadian Medication Incident Reporting and Prevention System (CMIRPS) (Hunt and others) (Abs) PPC-31

Medication error events in Ontario acute care hospitals (Marshman and others) (A) 243

Medication reconciliation—Safer healthcare now! (Etchells) (Abs) PPC-31

Medication safety alerts

(Greenall and Senders) (PP) 34

(Greenall) (PP) 81

(Poloway and Greenall) (PP) 206

Monitoring and reporting adverse drug reactions in India: Initiatives and contributions from pharmacists (Jose and Rao) (L) 155

Perceptions of patients and health care professionals about factors contributing to medication errors and potential areas for improvement (Hartnell and others) (A) 177

Risk assessment of medications in a pharmacy clean room (Dewhurst and others) (Abs) PPC-63

Safe medication practices (Wells and Hyland) (PP) 273

## **Medication systems**

MOXXI project: Linking pharmacists, physicians and patients (Winslade) (Abs) AGM-28

## **Medication systems, hospital**

Efficient prescription triage (Davis) (Abs) PPC-38

Implementation of medication reconciliation in a rehabilitation/complex continuing care facility (Karakolis and others) (Abs) PPC-55

Medication use and medication management standards (Taber) (Abs) AGM-28

Use of the patient medication list to ensure continuity of care for elective surgery patients (Saleemi) (Abs) PPC-51

## **MEDMARX Program See Adverse drug reaction reporting systems**

## **Memantine**

Controversies in the management of dementia (Mills) (Abs) PPC-30

## **Meningococcal vaccines**

Update on pediatric immunizations (Tjon) (Abs) PPC-44

## **Meperidine**

The effectiveness of interventions designed to reduce meperidine use in hospital (Groenstege) (Abs) PPC-56

## **Meropenem See Thienamycins**

## **Methicillin resistance**

Community-acquired MRSA: An emerging pathogen (Evans) (Abs) PPC-38

## **Mexican Association of Hospital Pharmacists See Asociación**

## **Mexicana de Farmacéuticos de Hospital**

## **Middle aged**

The use of benzodiazepines for insomnia in older adults: Effect of group education on readiness to change and knowledge (Leung and others) (Abs) PPC-50

## **Milrinone**

A drug use evaluation of milrinone in pediatric critical care patients (Bishara and others) (Abs) PPC-57

## **Multiple sclerosis**

Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) buccal spray: Experience in one patient (Min and others) (Abs) PPC-53

A new analgesic: Whole-plant-cannabis-based oral mucosal spray (Vanier) (Abs) AGM-31

## **Muscle relaxants, central**

Stopping medications in complex continuing care: The example of baclofen and dantrolene (Farrell and others) (A) 264

## **Muscle spasticity**

Stopping medications in complex continuing care: The example of baclofen and dantrolene (Farrell and others) (A) 264

## **Mycophenolic acid**

Genetic variation in UDP-glucuronosyltransferases and metabolism of mycophenolic acid in lung transplant recipients: A preliminary study (Ensom and others) (Abs) PPC-48

Limited sampling strategies for mycophenolic acid area-under-the-concentration-time curve in lung transplant recipients (Ensom and others) (Abs) PPC-48

Pharmacokinetic predictors of treatment efficacy and adverse effects following mycophenolate therapy in lung transplant recipients (Ensom and others) (Abs) PPC-49

## **Myocardial infarction**

In-hospital management of diabetes (Gordon) (Abs) PPC-28

Medication utilization rates after acute myocardial infarction in a cardiac rehabilitation population (Bucci and Oh) (Abs) PPC-53

Using acute myocardial infarction (AMI) guidelines to improve the care of your patients: Taking evidence to the bedside (Thompson) (Abs) PPC-29

## **Naloxone**

Stability of naloxone stored in aqueous diluents in syringes at 4°C and room temperature (23°C) (Walker and others) (Abs) PPC-62

## **Narcotics**

Medication safety alerts (Seki and Turner) (PP) 152

## **Neoplasms**

Pharmacoeconomic analysis of dalteparin vs. warfarin for the prevention of recurrent venous thromboembolic events in cancer patients (Dranitsaris and others) (Abs) 48

## **Neuralgia**

A new analgesic: Whole-plant-cannabis-based oral mucosal spray (Vanier) (Abs) AGM-31

Revue de la douleur neuropathique (Bouchard) (Abs) AGM-21

## **Neural tube defects**

Characteristics associated with adequate folic acid supplementation in a multicultural urban setting (Ferreira and others) (A) 22

## **Neutropenia**

Suspected drug interaction between clozapine and clarithromycin resulting in prolonged hospitalization (Loder and Lamoure) (Abs) PPC-50

## **Night blindness**

Night blindness secondary to vitamin A deficiency in a patient with cystic fibrosis and short-gut syndrome (Leung and others) (CR) 74



**Nitrofurantoin**

Stability of nitrofurantoin in extemporaneously compounded suspensions (Ensom and Decarie) (A) 29

**Obesity, morbid**

Ibutilide pretreatment to facilitate cardioversion of refractory atrial fibrillation in a patient with morbid obesity (Friesen and Ducas) (CR) 201

**Occupational exposure**

Challenges of NIOSH guidelines for pharmacy (Bornstein) (Abs) PPC-43

**Occupational health**

Challenges of NIOSH guidelines for pharmacy (Bornstein) (Abs) PPC-43

**Ofloxacin**

Management of hospital-acquired pneumonia at a tertiary-care teaching hospital (Seto and others) (A) 69

**Olanzapine** See **Benzodiazepines****Ontario**

Medication error events in Ontario acute care hospitals (Marshman and others) (A) 243

**Organ transplantation**

Inadequate empiric antibiotic therapy: Incidence and in-hospital mortality among critically-ill and solid-organ transplant patients (Hamandi and others) (Abs) AGM-39

**Orthopedics**

Comparison of a frail-friendly nomogram with physician-adjusted warfarin dosing for prophylaxis after orthopedic surgery on a geriatric rehabilitation unit (Bowles and Freter) (Abs) 49

**Osetamivir** See **Antiviral agents****Osteoporosis**

An evaluation of a multidisciplinary approach to the treatment of osteoporosis in patients following a low trauma hip fracture (Markowski and Richardson) (Abs) 48

Measuring the impact of pharmacist intervention: Results of patient education about osteoporosis after fragility fracture (Ho and others) (A) 184

Osteoporosis and the elderly—The use of bisphosphonates and parathyroid hormone (Brown) (Abs) PPC-29

**Pain**

Revue de la douleur neuropathique (Bouchard) (Abs) AGM-21

**Pain, intractable**

Testing the utility of a patient medication record in chronic pain patients (Ng and others) (Abs) PPC-57

**Palliative care**

Palliative care medication kits (Harris and others) (Abs) AGM-38

**Pantoprazole** See **Benzimidazoles****Paraproteinemias**

Lamotrigine induced blood dyscrasias—A case report (Yun and Lamourea) (Abs) PPC-54

**Parathyroid hormone**

Osteoporosis and the elderly—The use of bisphosphonates and parathyroid hormone (Brown) (Abs) PPC-29

**Patient care**

Pharmaceutical care practice—What's new? (Raman-Wilms) (Abs) PPC-26

**Patient education**

2006 recommendations of the Canadian Hypertension Education Program: Sound bite version (Canadian Hypertension Education Program) (PP) 148

Do bugs need drugs? A community program for wise use of antibiotics (Blondel-Hill and Fryters) (Abs) PPC-34

Evaluation of a comprehensive medication review program in urban senior centers (Chang and O'Connell) (Abs) PPC-53

An evaluation of a multidisciplinary approach to the treatment of osteoporosis in patients following a low trauma hip fracture (Markowski and Richardson) (Abs) 48

Measuring the impact of pharmacist intervention: Results of patient education about osteoporosis after fragility fracture (Ho and others) (A) 184

Randomized evaluation of patient medication teaching by videotape in a cardiac care unit (Sidhu and others) (Abs) 49

Self-management support: A pharmacist's journey from "sage on the stage" to "guide on the side" (Chong) (Abs) PPC-42

Understanding a patient's approach to medication use: An aid to tailoring medication information (Bajcar) (A) 119

The use of benzodiazepines for insomnia in older adults: Effect of group education on readiness to change and knowledge (Leung and others) (Abs) PPC-50

**Patient noncompliance** See **Treatment refusal****Patient safety** See **Quality of health care****Patient satisfaction**

Clinical outcomes and patient satisfaction of a pharmacist-managed emergency department-based outpatient deep vein thrombosis treatment program: 6-year results (Zed) (Abs) 49

**Peer review**

Value of peer review in publishing / La valeur des publications évaluées par les pairs (Vaillancourt) (E) 113 / 117

**Peptic ulcer**

The use of proton pump inhibitors for stress ulcer prophylaxis in critical care: A systematic review (Arbo and Tejani) (Abs) PPC-52

**Personnel selection**

Recruiting, training and evaluating pharmacists using key competencies (Tscheng and Gavura) (Abs) PPC-58

**Personnel training** See **Inservice training****Pertussis vaccine**

Update on pediatric immunizations (Tjon) (Abs) PPC-44

**Pharmacist-patient relations** See **Professional-patient relations****Pharmacists' aides**

Implementation of a "tech-check-tech" program for the preparation and labeling of selected IV admixture products prepared in the pharmacy clean room (Davies and Hales) (Abs) PPC-54

*Pharmacy Technician Certification Review and Practice Exam*. 2nd edition. Fred LY, editor (Quinn) (BR) 83

**Pharmacist's role** See **Professional role****Pharmacogenetics**

Drug metabolizing enzymes: Putting pharmacogenetics to practice (Ensom) (Abs) PPC-40

Drug toxicity, pharmacovigilance and tailored therapy (Stenton) (Abs) PPC-40

Genetic variation in UDP-glucuronosyltransferases and metabolism of mycophenolic acid in lung transplant recipients: A preliminary study (Ensom and others) (Abs) PPC-48

**Pharmacy technicians** See **Pharmacists' aides****Phentolamine**

Traitement d'une extravasation de phénytoïne avec la phentolamine (Châteauevert and others) (CR) 76

**Phenytoin**

Traitement d'une extravasation de phénytoïne avec la phentolamine (Châteauevert and others) (CR) 76

**Pneumococcal vaccines**

Update on pediatric immunizations (Tjon) (Abs) PPC-44

**Pneumonia**

Clinical practice guidelines for community-acquired pneumonia: An investigation into creation, characteristics, quality and compliance with production guides (Jewesson and Gill) (Abs) PPC-60

Management of hospital-acquired pneumonia at a tertiary-care teaching hospital (Seto and others) (A) 69

Respiratory fluoroquinolones for community-acquired pneumonia: Safety considerations (Carle) (Abs) AGM-31

Ventilator-associated pneumonia (Chant) (Abs) PPC-42

**Politics**

Run for it! A rookie candidate's federal election experience (Graham) (Abs) AGM-19

**Postoperative care**

Comparison of a frail-friendly nomogram with physician-adjusted warfarin dosing for prophylaxis after orthopedic surgery on a geriatric rehabilitation unit (Bowles and Freter) (Abs) 49

**Practice guidelines**

Adherence to Canadian Diabetes Association Clinical Practice Guidelines in an outpatient diabetes education centre (Crossman and others) (Abs) AGM-36

Clinical practice guidelines for community-acquired pneumonia: An investigation into creation, characteristics, quality and compliance with production guides (Jewesson and Gill) (Abs) PPC-60

A retrospective evaluation of adherence to guidelines for prevention of thromboembolic events in general medical inpatients (Patel and others) (A) 258

**Preceptorship**

Pharmacy residents developing teaching skills during the pharmacy practice residency program: A closer look at the issue (Gerber) (A) 14

**Pregnancy**

Characteristics associated with adequate folic acid supplementation in a multicultural urban setting (Ferreira and others) (A) 22

**Prejudice**

Racism in the health care system: Uncovering bias and developing cultural competency skills for pharmacists (Choudhury) (Abs) PPC-27



### **Preoperative care**

Implementation and a randomized controlled evaluation of pharmacist medication assessments in a surgical pre-admission clinic (Kwan and others) (Abs) PPC-63

### **Prescribing patterns See Professional practice**

### **Professional-patient relations**

Pharmacist? What pharmacist? / Pharmacien? Quel pharmacien? (Tisdale) (E) 235 / 239

### **Professional practice**

The use of ACE inhibitors,  $\beta$ -blockers, and warfarin in congestive heart failure: A community hospital study (Kwan and others) (A) 251

What strategies can pharmacists use to effectively impact prescribing practices? An evidence-based review (Martin) (Abs) PPC-36

### **Professional Practice Conference See Congresses**

### **Professional role**

CSHP position statement on pharmacist as head of hospital pharmacy (Dayneka) (L) 88

(Gray and others) (L) 86

(Johnson) (L) 87

Response from CSHP executive (Letwin and others) (L) 88

Leading change in pharmacy practice: The role of the pharmacist in the healthcare system (Tsuyuki) (Abs) AGM-19

Un long chemin sinueux / The long and winding road (Musing) (POR) 107 / 108

Pharmacist? What pharmacist? / Pharmacien? Quel pharmacien? (Tisdale) (E) 235 / 239

Pharmacist's role in medical mission to Guyana (Dole) (Abs) PPC-35

Role of the pharmacist in a lipid clinic (Semchuk) (Abs) PPC-33

The role of the pharmacist in cardiac rehab (Jorgenson) (Abs) PPC-34

### **Prostheses and implants**

The alphabet soup of cardiac devices (Chiu) (Abs) PPC-33

### **Proteinuria**

2006 recommendations of the Canadian Hypertension Education Program: Sound bite version (Canadian Hypertension Education Program) (PP) 148

### **Proton pumps**

Selection of a preferred proton pump inhibitor in the Canadian Forces: A drug use evaluation (Ma and others) (Abs) PPC-52

The use of proton pump inhibitors for stress ulcer prophylaxis in critical care: A systematic review (Arbo and Tejani) (Abs) PPC-52

### **Psychomotor agitation**

A description of the pharmacological management of acutely agitated patients in a psychiatric emergency department (Cheung and Chaiet) (Abs) PPC-59

Management of acute agitation and delirium: Are atypical antipsychotics just along for the ride? (Corrigan) (Abs) AGM-21

### **Public relations**

Pharmacist? What pharmacist? / Pharmacien? Quel pharmacien? (Tisdale) (E) 235 / 239

### **Publishing**

Editorial relationships: CSHP and *CJHP* / Relations éditoriales : SCPH et *JCPH* (Dupuis) (E) 171 / 175

Silk purses out of sows' ears: Turning your leftover projects and posters into real publications (Ensom) (Abs) AGM-26

### **Pulmonary disease, chronic obstructive**

The role of ipratropium in combination with tiotropium (Bayliff) (Abs) PPC-24

### **Pulmonary embolism**

Pharmacoeconomic analysis of dalteparin vs. warfarin for the prevention of recurrent venous thromboembolic events in cancer patients (Dranitsaris and others) (Abs) 48

A retrospective evaluation of adherence to guidelines for prevention of thromboembolic events in general medical inpatients (Patel and others) (A) 258

### **Quality assurance, health care**

Medication safety alerts (Greenall and Senders) (PP) 34

### **Quality of health care**

Anatomy and physiology of CPOE—Patient safety issues (Ritchie) (Abs) PPC-46

Bridging theory to practice: Practical considerations for implementing medication reconciliation strategies (Fernandes) (Abs) AGM-29

Establishment of an admission medication reconciliation program (Guimont and others) (Abs) AGM-38

Failure mode effects analysis of the pharmacy preparation of epidural syringes (Vaillancourt and others) (Abs) AGM-40

Measuring your department's progress in the advancement of pharmacy practice and patient safety (Macgregor and Roberts) (Abs) PPC-37

Medication error events in Ontario acute care hospitals (Marshman and others) (A) 243

Medication safety alerts

(Greenall and Senders) (PP) 34

(Poloway and Greenall) (PP) 206

(Seki and Turner) (PP) 152

Meeting the challenges of medication reconciliation in elective surgery patients: Verify, clarify, and reconcile (Carvalhana) (Abs) PPC-35

Perceptions of patients and health care professionals about factors contributing to medication errors and potential areas for improvement (Hartnell and others) (A) 177

Risk assessment of medications in a pharmacy clean room (Dewhurst and others) (Abs) PPC-63

Safe medication practices (Wells and Hyland) (PP) 273

### **Quinine**

IV quinine—Do you know how to get it? (Bubbar) (Abs) PPC-25

### **Racism See Prejudice**

### **Radiopharmaceuticals**

*Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine*. 2nd edition. Kowalsky RJ, Falen SW (Cornelissen and Kersemans) (BR) 154

### **Radius fractures**

Measuring the impact of pharmacist intervention: Results of patient education about osteoporosis after fragility fracture (Ho and others) (A) 184

### **Recombinant factor VIIa See Coagulants**

### **Rehabilitation**

Implementation and evaluation of a warfarin dosing service for rehabilitation medicine: Report from a pilot project (Chau and others) (A) 136

The role of the pharmacist in cardiac rehab (Jorgenson) (Abs) PPC-34

### **Renal dialysis**

A prospective randomized study of 4% citrate vs. heparin for the prevention of bacteremia and thrombosis in patients with hemodialysis catheters (Dojcinovic and others) (Abs) PPC-62

### **Research support**

CSHP R&E Foundation benefits from generous support of AstraZeneca (SN) 45

### **Residency See Internship and residency**

### **Review [publication type]**

Review of articles that will change your practice (Schuster) (Abs) AGM-23

Review of articles that will change your practice (Wilbur) (Abs) PPC-43

### **Risk factors**

A retrospective evaluation of adherence to guidelines for prevention of thromboembolic events in general medical inpatients (Patel and others) (A) 258

### **Rural health services**

Joint effort clinical pharmacy services in rural hospitals (Totton and others) (Abs) AGM-38

### **Seamless care See Continuity of patient care**

### **Seizures**

Seizures associated with fluoroquinolones: A series of case reports (Shortridge and others) (Abs) PPC-55

### **Self care**

The cost-effectiveness of patient self-managed versus physician-managed oral anticoagulation: A Bayesian approach (Sunderji and Marra) (Abs) 49

### **Serratia marcescens**

Management of hospital-acquired pneumonia at a tertiary-care teaching hospital (Seto and others) (A) 69

### **Sex offences**

Practice spotlight: Natalie Dayneka (PP) 275

### **Sexual assault See Sex offences**

### **Sleep initiation and maintenance disorders**

The use of benzodiazepines for insomnia in older adults: Effect of group education on readiness to change and knowledge (Leung and others) (Abs) PPC-50

### **Software**

Medication error events in Ontario acute care hospitals (Marshman and others) (A) 243

### **Sotalol**

Ibutilide pretreatment to facilitate cardioversion of refractory atrial fibrillation in a patient with morbid obesity (Friesen and Ducas) (CR) 201

### **Spasticity See Muscle spasticity**



## Spinal fractures

Measuring the impact of pharmacist intervention: Results of patient education about osteoporosis after fragility fracture (Ho and others) (A) 184

## Stability See Drug stability

### Staphylococcus aureus

Management of hospital-acquired pneumonia at a tertiary-care teaching hospital (Seto and others) (A) 69

### Staphylococcus infections

Community-acquired MRSA: An emerging pathogen (Evans) (Abs) PPC-38  
Management of hospital-acquired pneumonia at a tertiary-care teaching hospital (Seto and others) (A) 69

## Statins See Hydroxymethylglutaryl-CoA reductase inhibitors

## Stress ulcer See Peptic ulcer

## Stroke See Cerebrovascular accident

## Students, pharmacy

Enseigner et apprendre / Teach and be taught (Letwin) (POR) 55 / 56  
A missed exit ramp, an unforgettable year / Une bretelle d'accès manquée, une année réussie (Roy) (EDR) 52 / 53

## Sulfasalazine

Stability of sulfasalazine oral suspension (Lingertat-Walsh and others) (A) 194

## Suspensions

Stability of nitrofurantoin in extemporaneously compounded suspensions (Ensom and Decarie) (A) 29  
Stability of sulfasalazine oral suspension (Lingertat-Walsh and others) (A) 194

## Terminology

Medication safety alerts (Poloway and Greenall) (PP) 206

## Thienamycins

In vitro modeling of IV meropenem [500 mg q 6h vs. 1 g q8h] in acinetobacter bacteraemia (Marchesano and others) (Abs) PPC-64  
Lowering of serum valproic acid levels during concomitant therapy with meropenem: A clinically relevant drug interaction (Trope and others) (Abs) PPC-65

## Thrombocytopenia

Heparin-induced thrombocytopenia: Fact or fiction? (Williamson) (Abs) AGM-27  
Thrombocytopenie induite par l'héparine : mythe ou réalité? (Williamson) (Abs) AGM-30

## Thromboembolism

Impact of pharmacy intervention on venous thromboprophylaxis (Assaraf and others) (Abs) AGM-36

## Thrombosis

A prospective randomized study of 4% citrate vs. heparin for the prevention of bacteremia and thrombosis in patients with hemodialysis catheters (Dojcinovic and others) (Abs) PPC-62

## Tiotropium See Bronchodilator agents

## Trastuzumab See Antineoplastic agents

## Treatment refusal

Understanding a patient's approach to medication use: An aid to tailoring medication information (Bajcar) (A) 119

## Triazines

Lamotrigine induced blood dyscrasias—A case report (Yun and Lamoure) (Abs) PPC-54

## Tuberculosis

Tuberculosis (TB)—Emerging issues in pharmaceutical care (Chin) (Abs) AGM-25

## Tuberculosis, multidrug-resistant

Tuberculosis (TB)—Emerging issues in pharmaceutical care (Chin) (Abs) AGM-25

## Ulna fractures

Measuring the impact of pharmacist intervention: Results of patient education about osteoporosis after fragility fracture (Ho and others) (A) 184

## United States

A Canadian-trained pharmacist in the United States (Peeters) (L) 155  
Medication error events in Ontario acute care hospitals (Marshman and others) (A) 243  
Safe medication practices (Wells and Hyland) (PP) 273

## Valproic acid

Lowering of serum valproic acid levels during concomitant therapy with meropenem: A clinically relevant drug interaction (Trope and others) (Abs) PPC-65

## Venous thrombosis

Clinical outcomes and patient satisfaction of a pharmacist-managed emergency department-based outpatient deep vein thrombosis treatment program: 6-year results (Zed) (Abs) 49  
Pharmacoeconomic analysis of dalteparin vs. warfarin for the prevention of recurrent venous thromboembolic events in cancer patients (Dranitsaris and others) (Abs) 48  
A retrospective evaluation of adherence to guidelines for prevention of thromboembolic events in general medical inpatients (Patel and others) (A) 258

## Vitamin A deficiency

Night blindness secondary to vitamin A deficiency in a patient with cystic fibrosis and short-gut syndrome (Leung and others) (CR) 74

## Vitamin D

Measuring the impact of pharmacist intervention: Results of patient education about osteoporosis after fragility fracture (Ho and others) (A) 184

## Vitamin K<sub>1</sub>

Reversal of overanticoagulation with vitamin K<sub>1</sub>: A plea for oral administration (Vanier and Ngo) (A) 125

## Warfarin

Comparison of a frail-friendly nomogram with physician-adjusted warfarin dosing for prophylaxis after orthopedic surgery on a geriatric rehabilitation unit (Bowles and Freter) (Abs) 49  
Evaluation of the quality of warfarin patient information (Diamantouros and others) (Abs) AGM-35  
Implementation and evaluation of a warfarin dosing service for rehabilitation medicine: Report from a pilot project (Chau and others) (A) 136  
Pharmacoeconomic analysis of dalteparin vs. warfarin for the prevention of recurrent venous thromboembolic events in cancer patients (Dranitsaris and others) (Abs) 48  
Reversal of overanticoagulation with vitamin K<sub>1</sub>: A plea for oral administration (Vanier and Ngo) (A) 125  
The use of ACE inhibitors,  $\beta$ -blockers, and warfarin in congestive heart failure: A community hospital study (Kwan and others) (A) 251

## Author Index

**Abbott R** See **McCarthy J** Jt Auth

**Abdulmohsin S** See **Dib JG** Jt Auth

**Abesamis M** See **Lingertat-Walsh K** Jt Auth

**Abu-Laban RB** See **Samoy LJ** Jt Auth

**Ackman M** See **Gray M** Jt Auth

**Adams G** See **Methot M** Jt Auth

**Agiannidis V** See **Cheng G** Jt Auth

**Arbo T, Tejani A**

How to integrate evidence-based medicine into your daily practice: Help for the busy clinician (Abs) PPC-36

The RIPPLE effect: An introduction to evidence-based healthcare (Abs) 47

The use of proton pump inhibitors for stress ulcer prophylaxis in critical care: A systematic review (Abs) PPC-52

**Assaraf MI, Orng E, Roy JJ, Cohen E**

Impact of pharmacy intervention on venous thromboprophylaxis (Abs) AGM-36

**Atkinson S** See **Ferreira E** Jt Auth

**Bajcar J**

Understanding a patient's approach to medication use: An aid to tailoring medication information (A) 119

See also **Kwan Y** Jt Auth

**Balen RM** See **Samoy LJ** Jt Auth

**Banez C** See **Leung V** Jt Auth

**Barnett J**

The anatomy and physiology of CPOE (Abs) PPC-46

**Bartle B** See **Diamantouros A** Jt Auth

**Bassili AR** See **Ford BD** Jt Auth

**Bayliff CD**

The role of ipratropium in combination with tiotropium (Abs) PPC-24  
See also **Leung M** Jt Auth

**Beauchesne M-F, Nenciu LM, Dinh T-H, Tassé M, Fillion A**

Implantation d'un programme de continuité de soins pharmaceutiques pour la clientèle atteinte de maladies respiratoires (Abs) AGM-35

**Bernard O** See **Ensom MHH** Jt Auth

**Bhaloo S** See **Leblanc K** Jt Auth



- Bishara T, Seto W, Trope A, Parshuram C**  
A drug use evaluation of milrinone in pediatric critical care patients (Abs) PPC-57
- Blanchard C** See **Vaillancourt R** Jt Auth
- Blondel-Hill E, Fryters S**  
Do bugs need drugs? A community program for wise use of antibiotics (Abs) PPC-34
- Bornstein C**  
Are you a "leader-in-waiting"? / Êtes-vous un «leader en puissance»? (SN) 225 / 226
- Challenges of NIOSH guidelines for pharmacy (Abs) PPC-43
- What is USP Chapter <797> and how do I implement it? (Abs) PPC-26
- Bostwick TR** See **Pham CQD** Jt Auth
- Bouchard P**  
Revue de la douleur neuropathique (Abs) AGM-21
- Bowles SK, Freter SH**  
Comparison of a frail-friendly nomogram with physician-adjusted warfarin dosing for prophylaxis after orthopedic surgery on a geriatric rehabilitation unit (Abs) 49
- Brown TER**  
Osteoporosis and the elderly—The use of bisphosphonates and parathyroid hormone (Abs) PPC-29
- Brunton J** See **Hamandi B** Jt Auth
- Bubbar C**  
IV quinine—Do you know how to get it? (Abs) PPC-25
- Bucci C, Oh PIT**  
Medication utilization rates after acute myocardial infarction in a cardiac rehabilitation population (Abs) PPC-53
- Burry L, Ledger S**  
Highs, lows, & everything in between: Interpreting liver & kidney function in the acute & chronic setting (Abs) PPC-28
- Burton I** See **Pearson GJ** Jt Auth
- Burton JR** See **Pearson GJ** Jt Auth
- Bussi eres J-F** See **Ferreira E** Jt Auth
- Campbell A** See **Ho C** Jt Auth
- Canadian Hypertension Education Program**  
2006 recommendations of the Canadian Hypertension Education Program: Sound bite version (PP) 148
- Canadian Society of Hospital Pharmacists**  
Potential impact of implementing an entry-level Doctor of Pharmacy degree in Canada: 2005 update (Pos) 37
- Carle S**  
Respiratory fluoroquinolones for community-acquired pneumonia: Safety considerations (Abs) AGM-31
- Carvalhoana V**  
Meeting the challenges of medication reconciliation in elective surgery patients: Verify, clarify, and reconcile (Abs) PPC-35
- Chalet A** See **Cheung R** Jt Auth
- Chang F, O'Connell MB**  
Evaluation of a comprehensive medication review program in urban senior centers (Abs) PPC-53
- Chan J** See **Walker SE** Jt Auth
- Chan P** See **Lam J** Jt Auth
- Chant C**  
Ventilator-associated pneumonia (Abs) PPC-42
- Charbonneau F**  
Trastuzumab therapy for early breast cancer (Abs) PPC-41
- Ch ateauvert A, Labrecque K, Morissette D, Rioux A, Larouche G**  
Traitement d'une extravasation de ph nytoine avec la phentolamine (CR) 76
- Chau T, Rotbard M, King S, Li MM, Leong WA**  
Implementation and evaluation of a warfarin dosing service for rehabilitation medicine: Report from a pilot project (A) 136
- Chau T** See **Lam J** Jt Auth
- Cheng G, Agiannidis V, Fong T, Huynh V, Mach K, Sung M, Topors N, Wong K**  
Pharmacy seamless care project—What do community pharmacists need from an acute care hospital to improve continuity of pharmaceutical care? (Abs) PPC-57
- Cheng G** See **Min S** Jt Auth
- Cheung B** See **Lam J** Jt Auth
- Cheung R, Chalet A**  
A description of the pharmacological management of acutely agitated patients in a psychiatric emergency department (Abs) PPC-59
- Chin T**  
Tuberculosis (TB)—Emerging issues in pharmaceutical care (Abs) AGM-25
- Chiu J**  
The alphabet soup of cardiac devices (Abs) PPC-33
- Chong E**  
Self-management support: A pharmacist's journey from "sage on the stage" to "guide on the side" (Abs) PPC-42
- Chorney SG** See **Pearson GJ** Jt Auth
- Choudhury S**  
Racism in the health care system: Uncovering bias and developing cultural competency skills for pharmacists (Abs) PPC-27
- Clemons M** See **Dranitsaris G** Jt Auth
- Cohen E** See **Assaraf MI** Jt Auth
- Cornelissen B, Kersemans V**  
*Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine*. 2nd edition. Kowalsky RJ, Falen SW (BR) 154
- Cornish WR**  
*Pharmacist Disease Management: Diabetes*. 3rd edition. American Pharmacists Association (BR) 83
- Corrigan S**  
Management of acute agitation and delirium: Are atypical antipsychotics just along for the ride? (Abs) AGM-21
- C t  J-P**  
Le d fibrotide et la maladie h patique veino-occlusive, vous connaissez? (Abs) AGM-32
- Cranney A** See **Ho C** Jt Auth
- Crown N** See **Shortridge L** Jt Auth
- Crowther M** See **Dranitsaris G** Jt Auth
- Daley J** See **Methot M** Jt Auth
- Dalton B** See **Thirion DJG** Jt Auth
- Damota R** See **Wynne C** Jt Auth
- Dan L** See **Dresser L** Jt Auth
- Davies P** See **Dewhurst N** Jt Auth
- Davies P, Hales H**  
Implementation of a "tech-check-tech" program for the preparation and labeling of selected IV admixture products prepared in the pharmacy clean room (Abs) PPC-54
- Davis C**  
Efficient prescription triage (Abs) PPC-38
- Dayneka N**  
CSHP position statement on pharmacist as head of hospital pharmacy (L) 88
- Decarie D** See **Ensom MHH** Jt Auth
- Delano L** See **Gray M** Jt Auth
- Dewhurst N, Davies P, Wells J, Stojanovski J**  
Risk assessment of medications in a pharmacy clean room (Abs) PPC-63
- Diamantouros A, Bartle B, Geerts W, Kim L**  
Evaluation of the quality of warfarin patient information (Abs) AGM-35
- Dib JG, Abdulmohsin S**  
Avian influenza A (bird flu): Is the threat real? (L) 85
- Dinh T-H** See **Beauchesne M-F** Jt Auth
- Doherty D** See **Vaillancourt R** Jt Auth
- Dojcinovic I, Macrae JM, Shalansky S, Jung J, Kiaii M**  
A prospective randomized study of 4% citrate vs. heparin for the prevention of bacteremia and thrombosis in patients with hemodialysis catheters (Abs) PPC-62
- Dole R**  
Pharmacist's role in medical mission to Guyana (Abs) PPC-35
- Dranitsaris G, Clemons M, Verma S, Lau C, Vincent M**  
The development of a prediction tool for chemotherapy-induced anemia in breast cancer patients receiving adjuvant chemotherapy (Abs) 47-48
- Dranitsaris G, Vincent M, Crowther M**  
Pharmacoeconomic analysis of dalteparin vs. warfarin for the prevention of recurrent venous thromboembolic events in cancer patients (Abs) 48
- Dresser L, Dan L**  
Infective endocarditis—New guidelines and old questions (Abs) PPC-39
- Druteika D** See **Gray M** Jt Auth
- Ducas J** See **Friesen MH** Jt Auth
- Duffett M** See **Wynne C** Jt Auth
- Dumont M** See **Ferreira E** Jt Auth
- Dupuis LL**  
Editorial relationships: CSHP and *CJHP* / Relations  ditoriales : SCPH et *JCPH* (E) 171 / 175
- Edwards J** See **McCarthy J** Jt Auth
- Edwards S** See **McCarthy J** Jt Auth



- Ensom MHH**  
Drug metabolizing enzymes: Putting pharmacogenetics to practice (Abs) PPC-40  
A motivation letter / Une lettre de motivation (E) 61 / 65  
Silk purses out of sows' ears: Turning your leftover projects and posters into real publications (Abs) AGM-26
- Ensom MHH, Decarie D**  
Stability of nitrofurantoin in extemporaneously compounded suspensions (A) 29
- Ensom MHH, Marin J, Ting LSL, Partovi N, Levy RD**  
Cyclosporine absorption profiling and its limited sampling strategies in lung transplant recipients (Abs) PPC-49
- Ensom MHH, Ting LSL, Bernard O, Guillemette C**  
Genetic variation in UDP-glucuronosyltransferases and metabolism of mycophenolic acid in lung transplant recipients: A preliminary study (Abs) PPC-48
- Ensom MHH, Ting LSL, Partovi N, Levy RD, Riggs KW**  
Limited sampling strategies for mycophenolic acid area-under-the-concentration-time curve in lung transplant recipients (Abs) PPC-48
- Ensom MHH, Ting LSL, Tsang S, Partovi N, Levy RD**  
Pharmacokinetic predictors of treatment efficacy and adverse effects following mycophenolate therapy in lung transplant recipients (Abs) PPC-49
- Ensom RJ, Hall KW**  
Ethical conduct—Point and counterpoint (Abs) PPC-44
- Ethells E**  
Medication reconciliation—Safer healthcare now! (Abs) PPC-31
- Europa R** See **Lam J** Jt Auth
- Evans D** See **Ng A** Jt Auth
- Evans G**  
Community-acquired MRSA: An emerging pathogen (Abs) PPC-38
- Executive of the Hospital Pharmacy Residency Forum of Ontario**  
Position paper on the role of hospital residency programs in clinical training and professional development in the era of the proposed entry-level Doctor of Pharmacy program (Pos) 210
- Farrell B, Pora V, Babcock K**  
Stopping medications in complex continuing care: The example of baclofen and dantrolene (A) 264
- Farris J** See **Vaillancourt R** Jt Auth
- Feere D** See **Totton J** Jt Auth
- Fernandes O**  
Bridging theory to practice: Practical considerations for implementing medication reconciliation strategies (Abs) AGM-29  
See also **Kwan Y** Jt Auth
- Ferreira E**  
Nouveautés en contraception (Abs) AGM-22  
What is new in contraception? (Abs) AGM-20
- Ferreira E, Atkinson S, Gauthier L, Bussièrès J-F, Rey E, Dumont M**  
Characteristics associated with adequate folic acid supplementation in a multicultural urban setting (A) 22
- Fillion A** See **Beauchesne M-F** Jt Auth
- Fong T** See **Cheng G** Jt Auth
- Ford BD, Zoutman DE, Bassili AR**  
The confidentiality of community pharmacy records is at risk: A survey of designated pharmacy managers (Abs) PPC-61
- Freter SH** See **Bowles SK** Jt Auth
- Friedrich JO** See **Scales DC** Jt Auth
- Friesen MH, Ducas J**  
Ibutilide pretreatment to facilitate cardioversion of refractory atrial fibrillation in a patient with morbid obesity (CR) 201
- Fryters S** See **Blondel-Hill E** Jt Auth
- Gadawski M** See **Guimont P** Jt Auth
- Galonski M** See **Ng A** Jt Auth
- Gamulka B** See **Trope A** Jt Auth
- Gauthier L** See **Ferreira E** Jt Auth
- Gauthier S**  
Diagnosis, causes, course and Rx of Alzheimer's disease (AD) (Abs) AGM-23
- Gavura SR** See **Tscheng DZ** Jt Auth
- Geerts W** See **Diamantouros A** Jt Auth
- Genge R** See **Hartnell NR** Jt Auth
- Gerber P**  
Pharmacy residents developing teaching skills during the pharmacy practice residency program: A closer look at the issue (A) 14
- Gervais A** See **Ma J** Jt Auth
- Gill S** See **Jewesson PJ** Jt Auth
- Glennie H** See **Harris R** Jt Auth
- Gnanabakthan N** See **Marchesano R** Jt Auth
- Goldbert D** See **Lam J** Jt Auth
- Gordon A** See **Ng A** Jt Auth
- Gordon W**  
In-hospital management of diabetes (Abs) PPC-28
- Gould O** See **MacAulay S** Jt Auth
- Gourlay D** See **Ng A** Jt Auth
- Graham K**  
Run for it? A rookie candidate's federal election experience (Abs) AGM-19
- Gray M, Snatser M, Mysak T, Torok-Both L, Ackman M, Delano L, Druiteika D**  
CSHP position statement on pharmacist as head of hospital pharmacy (L) 86
- Greenall J**  
Medication safety alerts (PP) 81  
See also **Poloway L** Jt Auth
- Greenall J, Senders JW**  
Medication safety alerts (PP) 34
- Groenestege J**  
The effectiveness of interventions designed to reduce meperidine use in hospital (Abs) PPC-56
- Guillemette C** See **Ensom MHH** Jt Auth
- Guimont P, Gadawski M, MacDonald S**  
Establishment of an admission medication reconciliation program (Abs) AGM-38
- Halapy H**  
Practical considerations with glargine insulin (Abs) PPC-25
- Hales H** See **Davies P** Jt Auth
- Hall KW** See **Ensom RJ** Jt Auth
- Hamandi B, Holbrook A, Humar A, Brunton J, Papadimitropoulos M, Wong G**  
Inadequate empiric antibiotic therapy: Incidence and in-hospital mortality among critically-ill and solid-organ transplant patients (Abs) AGM-39
- Hamandi B** See **Zuberi M** Jt Auth
- Harrison J** See **Zuberi M** Jt Auth
- Harris R, Holt K, Glennie H**  
Palliative care medication kits (Abs) AGM-38
- Hartnell NR, MacKinnon NJ, Jones EJM, Genge R, Nestel MDM**  
Perceptions of patients and health care professionals about factors contributing to medication errors and potential areas for improvement (A) 177
- Hassouneh B** See **Labelle-Stimac S** Jt Auth
- Hindmarsh KW**  
Entry-level doctor of pharmacy program: The Canadian debate / Programme de doctorat professionnel de premier cycle en pharmacie : débat canadien (E) 9 / 12
- Ho C, Cranney A, Campbell A**  
Measuring the impact of pharmacist intervention: Results of patient education about osteoporosis after fragility fracture (A) 184
- Ho C, Tscheng D**  
Systematic protocol for managing drug information requests (Abs) PPC-61
- Ho C, Winkelbauer S**  
Retrospective methods of measuring practice change of pharmacists in continuing education (Abs) PPC-60
- Holbrook A** See **Hamandi B** Jt Auth
- Holt K** See **Harris R** Jt Auth
- Howie E** See **Kwan L** Jt Auth
- Huh J-H** See **Kwan Y** Jt Auth
- Humar A** See **Hamandi B** Jt Auth
- Hunt M, Hyland S, Loorand-Stiver L**  
Learning from medication incident data: The role of the Canadian Medication Incident Reporting and Prevention System (CMIRPS) (Abs) PPC-31
- Hunt P** See **Totton J** Jt Auth
- Hurn D** See **Kwan Y** Jt Auth
- Huynh V** See **Cheng G** Jt Auth
- Hyland S** See **Hunt M** Jt Auth; **Marshman JA** Jt Auth; **Wells B** Jt Auth
- Iazzetta J** See **Walker SE** Jt Auth
- Ibrahim S**  
Risks and benefits of atypical antipsychotics in the elderly (Abs) PPC-30
- Ingram S** See **Zuberi M** Jt Auth
- Irwin D** See **Vaillancourt R** Jt Auth

**Jewesson PJ, Gill S**

Clinical practice guidelines for community-acquired pneumonia: An investigation into creation, characteristics, quality and compliance with production guides (Abs) PPC-60

**Jewesson PJ, Koleba T, Marin J**

Entry-level PharmD degree programs in Canada: Some facts and stakeholder opinions (Abs) PPC-59

**Johnson N**

CSHP position statement on pharmacist as head of hospital pharmacy (L) 87

**Jones EJM** See **Hartnell NR** Jt Auth**Jorgenson D**

The role of the pharmacist in cardiac rehab (Abs) PPC-34

**Jose J, Rao PGM**

Monitoring and reporting adverse drug reactions in India: Initiatives and contributions from pharmacists (L) 155

**Joshi P** See **Lam J** Jt Auth**Jung J** See **Dojcinovic I** Jt Auth**Kang H** See **Rebellato N** Jt Auth**Karakolis P** See **Lam J** Jt Auth**Kelly D**

A practical approach to managing HIV drug interactions (Abs) PPC-32

**Kerseman V** See **Cornelissen B** Jt Auth**Kertland H**

Atrial fibrillation—Shocking new discoveries (Abs) PPC-32

See also **Rebellato N** Jt Auth

**Kiai M** See **Dojcinovic I** Jt Auth**Kim L** See **Diamantouros A** Jt Auth**King S** See **Chau T** Jt Auth**Kiss A** See **Scales DC** Jt Auth**Knauf KS** See **Pham CQD** Jt Auth**Koleba T** See **Jewesson PJ** Jt Auth**Koob R** See **Methot M** Jt Auth**Kwan D** See **Leung V** Jt Auth**Kwan L, Tjam EY, Smith S, Scott M, MacNaughton J, Howie E**

The use of ACE inhibitors,  $\beta$ -blockers, and warfarin in congestive heart failure: A community hospital study (A) 251

**Kwan Y, Fernandes O, Nageg J, Wong G, Huh J-H, Hurn D, Bajcar J**

Implementation and a randomized controlled evaluation of pharmacist medication assessments in a surgical pre-admission clinic (Abs) PPC-63

**Labelle-Stimac S, Stimac J, Hassouneh B**

Cardiovascular prevention and therapy: The mountain population report card—How good are we doing at home? (Abs) AGM-39

**Labrecque K** See **Châteauvert A** Jt Auth**Laforce T** See **Vaillancourt R** Jt Auth**Laing K** See **McCarthy J** Jt Auth**Lakhani A** See **Tejani AM** Jt Auth**Lalonde LD** See **Pearson GJ** Jt Auth**Lam J, Karakolis P, Chau T, Chan P, Cheung B, Europa R, Munger G, Goldbert D, Joshi P, Li M**

Implementation of medication reconciliation in a rehabilitation/complex continuing care facility (Abs) PPC-55

**Lamoure J** See **Loder J** Jt Auth; **Yun A** Jt Auth**Lam RWK** See **Marshman JA** Jt Auth**Laroche LF**

Exploring the impact of cultural differences on hospital pharmacists (Abs) PPC-23

**Larouche G** See **Châteauvert A** Jt Auth**Lau C** See **Dranitsaris G** Jt Auth**Law S** See **Lingertat-Walsh K** Jt Auth; **Marchesano R** Jt Auth; **Walker SE** Jt Auth**Leblanc K, Bhaloo S**

Development of a comprehensive training program for new pharmacist hires (Abs) PPC-64

**LeBlanc M** See **McCarthy J** Jt Auth**Ledger S** See **Burry L** Jt Auth**Leggatt P** See **Leung M** Jt Auth**Leong WA** See **Chau T** Jt Auth**Leslie D** See **Ng A** Jt Auth**Letwin S**

Enseigner et apprendre / Teach and be taught (POR) 55 / 56

Oh, tous ces endroits où vous irez! / Oh, the places you'll go! (POR) 227 / 228

See also **Tejani AM** Jt Auth

**Letwin S, Musing E, Roy M, Vaillancourt R, Wilson M**

CSHP position statement on pharmacist as head of hospital pharmacy: Response from CSHP executive (L) 88

**Letwin S, Musing E, Vaillant L**

Coming attractions: Previews to leadership (Abs) AGM-24

**Leung M, Bayliff CD, Paterson NAM, Leggatt P**

Night blindness secondary to vitamin A deficiency in a patient with cystic fibrosis and short-gut syndrome (CR) 74

**Leung V, Kwan D, Banez C, Nasmith L**

The use of benzodiazepines for insomnia in older adults: Effect of group education on readiness to change and knowledge (Abs) PPC-50

**Lévesque L**

Jongler avec les chiffres : comprendre les résultats des études (Abs) AGM-30

**Levy RD** See **Ensom MHH** Jt Auth**Li MM** See **Chau T** Jt Auth; **Lam J** Jt Auth**Lingertat-Walsh K, Walker SE, Law S, Abesamis M, Sales P**

Stability of sulfasalazine oral suspension (A) 194

**Loder J, Lamoure J**

Suspected drug interaction between clozapine and clarithromycin resulting in prolonged hospitalization (Abs) PPC-50

**Loewen P** See **Patel K** Jt Auth**Loorand-Stiver L** See **Hunt M** Jt Auth**MacAulay S, Saulnier L, Gould O**

Evaluation of clinical pharmacy services in the home care setting: A pharmacy pilot project (Abs) AGM-35

**MacDonald S** See **Guimont P** Jt Auth**Macgregor P, Roberts N**

Measuring your department's progress in the advancement of pharmacy practice and patient safety (Abs) PPC-37

**Mach K** See **Cheng G** Jt Auth**MacKinnon NJ** See **Hartnell NR** Jt Auth**MacNaughton J** See **Kwan L** Jt Auth**Macrae JM** See **Dojcinovic I** Jt Auth**Ma J, Gervais A, Vaillancourt R**

Selection of a preferred proton pump inhibitor in the Canadian Forces: A drug use evaluation (Abs) PPC-5

**Marchesano R, Walker S, Walker SE, Gnanabakthan N, Law S, Watt C, Simor A**

In vitro modeling of IV meropenem [500 mg q 6h vs. 1g q8h] in acinetobacter bacteraemia (Abs) PPC-64

**Marin J** See **Ensom MHH** Jt Auth; **Jewesson PJ** Jt Auth**Markowski T, Richardson J**

An evaluation of a multidisciplinary approach to the treatment of osteoporosis in patients following a low trauma hip fracture (Abs) 48

**Marquis C**

L'étomidate a-t-il une place dans nos chariots de réanimation? (Abs) AGM-32

**Marra C** See **Sunderji R** Jt Auth**Marra F**

Antibiotic consumption in populations: How does a North American jurisdiction compare with Europe? (Abs) 48

**Marshman JA, U DK, Lam RWK, Hyland S**

Medication error events in Ontario acute care hospitals (A) 243

**Martelli B** See **Vaillancourt R** Jt Auth**Martin JE**

What strategies can pharmacists use to effectively impact prescribing practices? An evidence-based review (Abs) PPC-36

**McCarthy J, Edwards J, Edwards S, LeBlanc M, Abbott R, Laing K**

The evaluation and implementation of a process to identify patients eligible for an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone sensitive breast cancer patients in Newfoundland and Labrador (NL) (Abs) AGM-35

**McCroly PH, Jr**

Disaster planning: Lessons learned from Hurricane Katrina (Abs) AGM-33

**McLellan C** See **Slagel K** Jt Auth**Methot M, Ropchan G, Adams G, Koob R, Daley J**

Carbamazepine toxicity related to amiodarone use prior to cardiac surgery (Abs) PPC-55

**Methot M** See **Slagel K** Jt Auth**Michenko M** See **Wynne C** Jt Auth**Milliken D** See **Walker SE** Jt Auth**Mills A**

Controversies in the management of dementia (Abs) PPC-30

**Min S, Simmonds WF, Cheng G**

Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) buccal spray: Experience in one patient (Abs) PPC-53





- Miyata M** See **Tejani AM** Jt Auth  
**Morissette D** See **Châteauvert A** Jt Auth  
**Munger G** See **Lam J** Jt Auth  
**Musing ELS**  
 Un long chemin sinueux / The long and winding road (POR) 107 / 108  
 A wrinkle in time / Un signe du temps (POR) 288 / 289  
 See also **Letwin S** Jt Auth  
**Musing ELS, Tseng A, Wong G**  
 Development of an educational sabbatical program for pharmacists (Abs) 47  
**Mysak T**  
 Practical tips in stroke management (Abs) PPC-27  
 See also **Gray M** Jt Auth
- Nagge J**  
 ASA resistance: A laboratory or clinical phenomenon (Abs) PPC-26  
 See also **Kwan Y** Jt Auth  
**Nakagawa B** See **Tejani AM** Jt Auth  
**Nakagawa R**  
 National Pharmaceuticals Strategy (Abs) AGM-23  
**Nasmith L** See **Leung V** Jt Auth  
**Nenciu LM** See **Beauchesne M-F** Jt Auth  
**Nestel MDM** See **Hartnell NR** Jt Auth  
**Ng A, Galonski M, Gordon A, Evans D, Gourlay D, Singh S, Dan L**  
 Testing the utility of a patient medication record in chronic pain patients (Abs) PPC-57  
**Ng J, Ong S**  
 The ABCs of RBCs: An interactive talk about anemia in chronic kidney disease (Abs) PPC-37  
**Ng V**  
 A systematic review of the risk of acquired protein C resistance in women taking third-generation over second-generation combination oral contraceptives (Abs) PPC-51  
**Ngo T-T** See **Vanier M-C** Jt Auth
- O'Connell MB** See **Chang F** Jt Auth  
**Oh PIT** See **Bucci C** Jt Auth  
**Ong S** See **Ng J** Jt Auth  
**Orng E** See **Assaraf MI** Jt Auth
- Papadimitropoulos M** See **Hamandi B** Jt Auth  
**Parshuram C** See **Bishara T** Jt Auth; **Trope A** Jt Auth  
**Partovi N** See **Ensom MHH** Jt Auth; **Sidhu K** Jt Auth  
**Patel K, Loewen P, Wilbur K**  
 A retrospective evaluation of adherence to guidelines for prevention of thromboembolic events in general medical inpatients (A) 258  
**Paterson NAM** See **Leung M** Jt Auth  
**Pearson GJ**  
 Cardiac diagnostic testing—A primer for pharmacists (Abs) PPC-24  
**Pearson GJ, Stewart GG, Burton I, Chorney SG, Tymchak WJ, Lalonde LD, Burton JR**  
 Successful treatment to guideline recommended LDL-cholesterol targets in heart transplant recipients (Abs) PPC-64  
**Peeters MJ**  
 A Canadian-trained pharmacist in the United States (L) 155  
**Perreault MM**  
 Use of recombinant factor VIIa in critically ill patients (Abs) PPC-45  
**Pham CQD**  
 Infliximab: New role in ulcerative colitis (Abs) AGM-20  
 Infliximab : nouveau rôle dans le traitement de la colite ulcéreuse (Abs) AGM-22  
**Pham CQD, Regal RE, Bostwick TR, Knauf KS**  
 Acid suppressive therapy use on an inpatient internal medicine service (Abs) AGM-34  
**Pharand C**  
 Approach to anticoagulation in acute coronary syndromes (Abs) AGM-29  
 Nouvelles approches d'anticoagulation en syndromes coronariens aigus (Abs) AGM-25  
**Pickering J, Semchuk W**  
 ACEI versus ARB in high-risk vascular patients (Abs) PPC-33  
**Pitre M** See **Thirion DJG** Jt Auth  
**Poloway L**  
 Implementation of a prohibited list of abbreviations in the David Thompson Health Region (Abs) AGM-40  
**Poloway L, Greenall J**  
 Medication safety alerts (PP) 206  
**Pora V** See **Farrell B** Jt Auth  
**Pritchard K** See **Totton J** Jt Auth
- Quinn I**  
*Pharmacy Technician Certification Review and Practice Exam.*  
 2nd edition. Fred LY, editor (BR) 83
- Rachlis A** See **Seto A** Jt Auth  
**Raman-Wilms L**  
 Pharmaceutical care practice—What's new? (Abs) PPC-26  
**Rao PGM** See **Jose J** Jt Auth  
**Rebellato N, Kang H, Kertland H**  
 Development of a strategy for safe dofetilide prescribing and monitoring (Abs) PPC-58  
**Redelmeier DA** See **Scales DC** Jt Auth  
**Regal RE** See **Pham CQD** Jt Auth  
**Rey E** See **Ferreira E** Jt Auth  
**Richardson J** See **Markowski T** Jt Auth  
**Rideout J** See **Tejani AM** Jt Auth  
**Riggs KW** See **Ensom MHH** Jt Auth  
**Rioux A** See **Châteauvert A** Jt Auth  
**Ritchie M**  
 Anatomy and physiology of CPOE—Patient safety issues (Abs) PPC-46  
**Roberts JM** See **Samoy LJ** Jt Auth  
**Roberts N** See **Macgregor P** Jt Auth  
**Ropchan G** See **Methot M** Jt Auth  
**Rotbard M** See **Chau T** Jt Auth  
**Roy JJ** See **Assaraf MI** Jt Auth  
**Roy M**  
 A missed exit ramp, an unforgettable year / Une bretelle d'accès manquée, une année réussie (EDR) 52 / 53  
**Roy M** See **Letwin S** Jt Auth
- Saleemi Z**  
 Use of the patient medication list to ensure continuity of care for elective surgery patients (Abs) PPC-51  
**Sales P** See **Lingertat-Walsh K** Jt Auth  
**Samoy LJ, Zed PJ, Wilbur K, Balen RM, Abu-Laban RB, Roberts JM**  
 Drug-related hospitalization to a tertiary care internal medicine service: A prospective study (Abs) 47  
**Saulnier L** See **MacAulay S** Jt Auth  
**Scales DC, Friedrich JO, Kiss A, Sibbald WJ, Redelmeier DA**  
 Methodological issues in critical care clinical trials (Abs) PPC-45  
**Schuster BG**  
 Review of articles that will change your practice (Abs) AGM-23  
**Scott M** See **Kwan L** Jt Auth  
**Seki J, Turner L**  
 Medication safety alerts (PP) 152  
**Semchuk W**  
 Role of the pharmacist in a lipid clinic (Abs) PPC-33  
 See also **Pickering J** Jt Auth  
**Senders JW** See **Greenall J** Jt Auth  
**Seto A, Walker S, Rachlis A**  
 Management of hospital-acquired pneumonia at a tertiary-care teaching hospital (A) 69  
**Seto W** See **Bishara T** Jt Auth  
**Shalansky S** See **Dojcinovic I** Jt Auth  
**Shin H-SH**  
 The systemic overview of the relative benefits and risks of insulin sliding scale dosing regimen in stable patients with type 2 diabetes in hospitals (Abs) PPC-56  
**Shortridge L, Crown N, Bayliff CD, Young B**  
 Seizures associated with fluoroquinolones: A series of case reports (Abs) PPC-55  
**Sibbald WJ** See **Scales DC** Jt Auth  
**Sidhu K, Sunderji R, Partovi N**  
 Randomized evaluation of patient medication teaching by videotape in a cardiac care unit (Abs) 49  
**Simmonds WF** See **Min S** Jt Auth  
**Simor A** See **Marchesano R** Jt Auth  
**Singh S** See **Ng A** Jt Auth  
**Slagel K, Methot M, McLellan C**  
 A drug use evaluation comparing bivalirudin and the combination of heparin plus eptifibatid in elective percutaneous coronary intervention (Abs) AGM-34  
**Slavik RS**  
 Evidence-based medicine workshop—Appraising systematic reviews (Abs) AGM-26  
**Smith S** See **Kwan L** Jt Auth  
**Snaterse M** See **Gray M** Jt Auth



- Sorfleet C** See **Vaillancourt R** Jt Auth  
**Stenton SB**  
Drug toxicity, pharmacovigilance and tailored therapy (Abs) PPC-40  
**Stewart GG** See **Pearson GJ** Jt Auth  
**Stimac J** See **Labelle-Stimac S** Jt Auth  
**Stojanovski J** See **Dewhurst N** Jt Auth  
**Sunderji R, Marra C**  
The cost-effectiveness of patient self-managed versus physician-managed oral anticoagulation: A Bayesian approach (Abs) 49  
**Sunderji R** See **Sidhu K** Jt Auth  
**Sung M** See **Cheng G** Jt Auth
- Taber S**  
Medication use and medication management standards (Abs) AGM-28  
**Talia L** See **Vaillancourt R** Jt Auth  
**Tassé M** See **Beauchesne M-F** Jt Auth  
**Tchen M** See **Vaillancourt R** Jt Auth  
**Tejani AM, Nakagawa B, Letwin S, Rideout J, Miyata M, Lakhani A**  
Evidence and a regional drug formulary: The Fraser Health Authority experience (Abs) AGM-37  
**Tejani A** See **Arbo T** Jt Auth  
**Thirion DJG**  
Appel aux armes ! Une mise à jour sur les pratiques contre l'invasion des nouvelles maladies infectieuses (Abs) AGM-21  
Holding the line! Updates on emerging infections (Abs) AGM-19  
**Thirion DJG, Dalton B, Pitre M**  
Standardized methods for measuring drug use: Making cents of the data! (Abs) AGM-27  
**Thomas M** See **Vaillancourt R** Jt Auth  
**Thompson A**  
Using acute myocardial infarction (AMI) guidelines to improve the care of your patients: Taking evidence to the bedside (Abs) PPC-29  
**Ting LSL** See **Ensom MHH** Jt Auth  
**Tisdale JE**  
Pharmacist? What pharmacist? / Pharmacien? Quel pharmacien? (E) 235 / 239  
**Tjam EY** See **Kwan L** Jt Auth  
**Tjon JA**  
Update on pediatric immunizations (Abs) PPC-44  
**Topors N** See **Cheng G** Jt Auth  
**Torok-Both L** See **Gray M** Jt Auth  
**Totton J, Hunt P, Pritchard K, Feere D**  
Joint effort clinical pharmacy services in rural hospitals (Abs) AGM-38  
**Trope A, Gamulka B, Walsh W, Verjee Z, Parshuram C**  
Lowering of serum valproic acid levels during concomitant therapy with meropenem: A clinically relevant drug interaction (Abs) PPC-65  
**Trope A** See **Bishara T** Jt Auth  
**Tsang S** See **Ensom MHH** Jt Auth  
**Tscheng DZ** See **Ho C** Jt Auth  
**Tscheng DZ, Gavura SR**  
Recruiting, training and evaluating pharmacists using key competencies (Abs) PPC-58  
**Tseng A** See **Musing E** Jt Auth  
**Tsuyuki RT**  
Leading change in pharmacy practice: The role of the pharmacist in the healthcare system (Abs) AGM-19  
**Turner L** See **Seki J** Jt Auth  
**Tymchak WJ** See **Pearson GJ** Jt Auth
- U DK** See **Marshman JA** Jt Auth
- Vaillancourt R** See **Letwin S** Jt Auth; **Ma J** Jt Auth  
**Vaillancourt R**  
Souvenirs heureux / Looking back with pride (POR) 163 / 164  
Value of peer review in publishing / La valeur des publications évaluées par les pairs (E) 113 / 117  
**Vaillancourt R, Blanchard C, Wong E, Tchen M, Martelli B, Farris J, Laforce T, Talia L, Sorfleet C**  
Failure mode effects analysis of the pharmacy preparation of epidural syringes (Abs) AGM-40  
**Vaillancourt R, Irwin D, Wong E, Doherty D, Thomas M, Sorfleet C**  
A retrospective comparison of variable concentrations versus standardized concentrations on 24-hour drug infusion volumes in a paediatric intensive care unit (Abs) AGM-40
- Vaillant I** See **Letwin S** Jt Auth  
**Vanier M-C**  
A new analgesic: Whole-plant-cannabis-based oral mucosal spray (Abs) AGM-31  
**Vanier M-C, Ngo T-T**  
Reversal of overanticoagulation with vitamin K<sub>1</sub>: A plea for oral administration (A) 125  
**Verjee Z** See **Trope A** Jt Auth  
**Verma S** See **Dranitsaris G** Jt Auth  
**Vincent M** See **Dranitsaris G** Jt Auth
- Walker S** See **Marchesano R** Jt Auth; **Seto A** Jt Auth  
**Walker SE**  
A time of transition / Un temps de transition (E) 4 / 6  
See also **Lingertat-Walsh K** Jt Auth; **Marchesano R** Jt Auth  
**Walker SE, Chan J, Law S**  
Stability of naloxone stored in aqueous diluents in syringes at 4°C and room temperature (23°C) (Abs) PPC-62  
**Walker SE, Iazzetta J, Law S**  
Irinotecan stability in vials following puncture when stored at 23°C or 4°C (Abs) AGM-36  
Physical compatibility of pantoprazole (PANTO® IV) with 36 medications during y-site simulation (Abs) AGM-37  
**Walker SE, Milliken D, Law S**  
Stability of bortezomib vials reconstituted with 0.9% sodium chloride at 4°C and room temperature (23°C) (Abs) PPC-62  
**Walsh W** See **Trope A** Jt Auth  
**Watt C** See **Marchesano R** Jt Auth  
**Wells B, Hyland S**  
Safe medication practices (PP) 273  
**Wells J** See **Dewhurst N** Jt Auth  
**Wilbur K**  
Review of articles that will change your practice (Abs) PPC-43  
See also **Patel K** Jt Auth; **Samoy LJ** Jt Auth  
**Williamson D**  
Heparin-induced thrombocytopenia: Fact or fiction? (Abs) AGM-27  
Thrombocytopenie induite par l'héparine : mythe ou réalité? (Abs) AGM-30  
**Wilson M** See **Letwin S** Jt Auth  
**Winkelbauer S** See **Ho C** Jt Auth  
**Winslade N**  
MOXXI Project: Linking pharmacists, physicians and patients (Abs) AGM-28  
**Woloschuk DMM**  
Competency-based accreditation standards for residency training (L) 214  
The future of residency training in Canada (Abs) AGM-24  
**Wong E** See **Vaillancourt R** Jt Auth  
**Wong G** See **Hamandi B** Jt Auth; **Kwan Y** Jt Auth; **Musing E** Jt Auth  
**Wong K** See **Cheng G** Jt Auth  
**Wynne C, Damota R, Michenko M, Duffett M**  
Implementation of an insulin protocol in adult critically ill patients (Abs) PPC-51
- Young B** See **Shortridge L** Jt Auth  
**Yun A, Lamoure J**  
Lamotrigine induced blood dyscrasias—A case report (Abs) PPC-54
- Zed PJ**  
Clinical outcomes and patient satisfaction of a pharmacist-managed emergency department-based outpatient deep vein thrombosis treatment program: 6-year results (Abs) 49  
**Zed PJ** See **Samoy LJ** Jt Auth  
**Zoutman DE** See **Ford BD** Jt Auth  
**Zuberi M**  
“Medical Internet” resources and implications for future practice (Abs) PPC-23  
Use of concept maps to enhance learning within a traditional model of practice-based pharmacy education (Abs) AGM-40  
**Zuberi M, Hamandi B, Harrison J, Ingram S**  
A retrospective comparison of medication regimen complexity in renal transplant recipients receiving calcineurin inhibitors (Abs) AGM-39

